


LIFE SCIENCES: TRENDS FOR THE FUTURE

Infosys® | Knowledge Institute



#BreakthroughsForLife



Table of contents

Foreword	4
Executive summary	6
Trend 1: Generative AI promises innovation and enhancements to the life sciences value chain	10
Trend 2: AI and behavioral science transform digital therapeutics	18
Trend 3: From traveling salespeople to digital feedback loops: The future of life sciences sales and marketing	26
Trend 4: The increase in virtual trials tips the balance toward remote interactions, improves patient data, and lowers the cost of clinical trials	34
Trend 5: The rise of intelligent pharma manufacturing	42
Trend 6: The new pharma supply chain: Collaboration and data	50
Trend 7: Knowledge sharing and data integration build stronger healthcare ecosystems	58

Foreword



Subhro Mallik

Executive vice president and
head of life sciences, Infosys

The life sciences industry is on the brink of a new era of innovation. From AI-powered clinical trials to digital patient companions, every industry process and touchpoint is being reimagined or upended.

There's never been a more exciting time in life sciences. Whether you're in the pharmaceutical, biotech, medical devices, or animal health sector, there's abundant opportunity to catalyze change in every part of the value chain. Data-driven platforms can uncover gene therapies, mobile apps can aid remote patient management, and cloud platforms can drive valuable supply-chain synergies.

The biggest needle-mover though, seems to be generative AI. It will drive much-needed efficiency gains in many areas — research, drug safety, trial reporting, pricing, patient-centricity, and skills gaps across the enterprise. As well as driving efficiency, generative AI will also enable creativity, helping those working in life sciences to correlate research outcomes faster and engage with patients better.


This isn't just giddy optimism. It is a belief formed by having seen the transformative impact digital, cloud and AI have had for our life sciences clients and their customers. This journal shares our insights and expertise with you. Our leaders and experts have drawn from their experiences working with industry chiefs to help them build their strategies and navigate their landscapes. This journal delivers our perspective on the technologies we think are profoundly changing the way we in the life sciences sector do our work.

Even as digital technology plays a greater role in pioneering innovation, synergizing operations, and personalizing journeys, we believe the essence of the industry remains the same as it has over decades — which is to enable breakthroughs for life.

It is in this spirit that we seek to serve at Infosys. I hope you find that spirit in our journal, and that its insights help you respond to the challenges and opportunities that will define the transformation agenda ahead.

#BreakthroughsForLife





Executive summary

Life sciences is teeming with innovation, from new techniques for drug discovery and improvements in supply chain and manufacturing to better data integration across the ecosystem. At the same time, drug shortages, high costs of healthcare, and data privacy risks threaten to stifle this growth. Fortunately, digital advances and transformative technologies such as artificial intelligence (AI) and intelligent manufacturing are accelerating the evolution of this industry and improving lives of billions.

Infosys has created this inaugural life sciences journal to share our perspectives and aid industry leaders on their decisions related to these strategic topics.


Through research, workshops, and executive interviews, we identified seven trends at the

intersection of digital technologies and life sciences. We additionally surveyed 100 life sciences executives at leading firms on their views for planned investments among these seven trends.

Although generative AI is stealing the spotlight, demonstrating the impact it has had in such a short time, each of these seven trends will reshape the life sciences industry over the next two to three years. Nearly three-quarters (73%) of leaders we surveyed say their firms will spend between \$10 million and \$50 million on each of these areas in the next two years, and an additional 20% will spend more than \$50 million.

These seven trends will enable leaders to harness rapid change, transform their enterprises, and deliver breakthroughs for life.

1. **Generative AI** promises to drive innovation and efficiency, while requiring enterprises to enact rigorous safeguards for responsible and explainable AI. From chatbots and AI-assisted research agents, to sales representatives engaging with healthcare professionals to create rapid summaries of submission-related content, we anticipate that innovations built with generative AI will impact the entire life sciences value chain — with patients being the primary beneficiaries.
2. **Digital therapeutics** will continue to grow rapidly for the next decade. These new tools will drive personalization, improve efficacy of existing medicines and devices, increase access to patient data, rely on data across the patient journey, and strengthen brand positioning amid the consumerization of healthcare.
3. **Virtualization of sales and marketing** transformed how organizations engage with healthcare providers. The shift to virtual engagements initially driven by the pandemic has increased the adoption of hybrid sales professionals powered by digital tools. This is leading to better insights and a continuous feedback loop that allow sales reps to meet physicians at their point and time of need — first multichannel and then omnichannel.
4. **Hybrid and virtual clinical trials** will become the norm, saving time and money, and creating a diverse patient pool that leads to more accurate results, accelerates enrollment, and reduces patient dropout rates. Advancements in at-home data-




capture technologies, wearables, and remote monitoring will increase patient satisfaction and also create new opportunities from the large volume of data collected.

5. **Intelligent manufacturing** positions life sciences to move from industry tech laggard to leader as production of new therapeutics drives faster progress than other industries. The application of internet of things, big data, and AI will enable real-time process adjustment capabilities and optimize quality control to increase product efficiency, at the same time enabling simplification of regulatory compliance.
6. **Supply chain resilience** will become a necessary criterion as organizations manage their diverse portfolio of small- and large-molecule drugs. A shift to enterprise platforms that deliver planning at global scale while ensuring visibility of raw material and drug products at regional scale will enable the vision of a flexible supply chain network meeting their growth needs.

7. Data and insight integration across the healthcare ecosystem will lead to transformative new products and commercial successes as data, models, and knowledge are shared across the value chain of an organization. AI will play a big role in this integration, especially for data

navigation, linkage, and interoperability. Recent years have seen a significant adoption of digital technologies within the life sciences ecosystem, and I am confident that these trends will be a substantial enabler for change within organizations while enriching the lives of patients.





•

Generative AI burst into the mainstream in 2023, and companies are rapidly experimenting and developing exciting use cases, such as an AI tool capable of detecting tiny cancers almost invisible to the human eye. Tools like these have tremendous

potential to transform life sciences in this decade. We anticipate that innovations built with generative AI will impact the entire life sciences value chain, from drug discovery to distribution – with drug development being the next frontier. Boston Consulting Group

has projected that the generative AI market in healthcare will grow from \$1 billion now to \$22 billion by 2027, a compound rate of 85%. Potential benefits include fewer bottlenecks, lower administrative burdens, faster drug discovery, and improved data analysis.

However, generative AI introduces and amplifies ongoing concerns about responsible AI, particularly data quality, privacy, ethics, and security. In life sciences, these risks could compromise patient records and drug safety. Life sciences companies are likely to face new regulations around AI, evolving as the technology matures and societal implications are better understood.

Life sciences firms must walk a tightrope of simultaneous rapid experimentation and risk mitigation to unlock value responsibly from generative AI. To realize business value while minimizing risk, it is imperative to understand patient impact, ensure ownership of AI models, and maintain strong data and AI governance. Ethics, governance, and transparency are vital to earn trust from the medical community, regulators, and the general public — and they are central to an AI-first approach. Looking ahead, we believe that taking this approach will lead to reduced time to market and will facilitate managing the increasing complexity in drugs, regulatory requirements, and patient expectations.

Exciting potential

As in all industries, generative AI investment in life sciences exploded in 2023. As companies across sectors continue to increase experimentation and use cases,

2024 looks to be the year when many get to grips with this transformative technology. In March 2024, the UK's National Health Service piloted an AI tool called Mia to detect cancer in the mammograms of more than 10,000 women. It found tiny tumors nearly invisible to the human eye in 11 of the mammograms. In another use case, a deep learning AI algorithm detected autism spectrum disorder using retinal images with a claimed 100% accuracy. However, since AI could spur overdiagnosis and associated concerns, providers will also need governance and a risk-based approach, such as humans-in-the-loop, to deploy these capabilities responsibly.

Transformative use cases such as these indicate generative AI has the potential to impact every part of the life sciences value chain, from drug discovery to manufacturing. For example, our own work with AI assistants in clinical and regulatory operations indicates that companies can significantly reduce time to market. Executives' belief in this potential is reflected by their increased investment in AI. Enterprise spending on generative AI services, software and infrastructure is anticipated to increase from \$16 billion in 2023 to \$143 billion by 2027 at a compound annual growth rate of 73.3%. Life sciences and healthcare have increased spending in similar fashion. Research and development in generative AI use cases, which included protein and molecule generation and synthetic healthcare datasets, reached \$983 million in fundraising in 2023. Meanwhile, \$216 million was raised for commercial and medical projects within verticals such as predictive tools, patient-doctor interaction summaries, and patient data analysis. Life sciences leaders

are spending big on generative AI and have plans to accelerate even more.


According to an Infosys survey of 100 life sciences executives, 73% of respondents say they will spend \$15 million a year or more on generative AI — more than they plan to spend on other technology initiatives.

Nearly one-third (29%) indicate that their investment in generative AI will grow by more than 40% from 2024 to 2026. As shown in Figure 1, spending amounts and projected spend change are beginning to diverge among life sciences businesses. The most popular industry application for generative AI is in drug discovery and early-stage development, which polled as the top choice for investments over the next five years.

Generative AI in drug discovery

Drug discovery is a high-risk, high-reward proposition. The discovery process can take up to 14 years, and 97% of potential cancer drugs fail during clinical trials. Generative AI can improve several stages of the discovery process through

Figure 1. Although AI spending is up, the cost and complexity of putting AI to work splits enterprises into distinct cohorts



Source: Infosys Knowledge Institute

applications such as generative models for drug discovery, reinforcement learning, and drug-disease associations.

Life sciences researchers and companies have

“

For the first time in human history, biology has the opportunity to be engineering, not science ... we're going to have incredible tools that bring the world of biology into the world of computer science. And that is going to be profound.

Jensen Huang

CEO, NVIDIA, speaking at University of California, Berkeley

”

already put generative AI to practical use in their fields of expertise. Stanford Medicine has proven this point with SyntheMol, a generative AI model providing new drugs for antibiotic-resistant bacteria. Insilico developed an anti-fibrotic small molecule inhibitor that has progressed from origins in a generative AI algorithm to a Phase II clinical trial.

Merck has used a small molecule generative AI tool produced by Variational AI to explore a wider range of potentially therapeutic compounds. Insilico managed to develop its pulmonary fibrosis drug candidate within 18 months using Pharma.AI. A year later, in 2022, the company announced that its total time from target discovery to phase I took less than 30 months, thanks to its generative AI.

Within the same sector, firms Ordaös Bio and Absci are focusing on the use of generative AI to further pharma breakthroughs within the protein vertical. Ordaös Bio is using deep learning and proprietary “generative perception systems” to create mini-proteins for pharma and biotech companies. Absci uses zero-shot learning — a type of deep learning that makes inferences about concepts it has not been directly shown — to validate and design de novo antibody candidates to reduce cycle time for drug discovery.

NVIDIA is collaborating with Amgen, the pharma giant specializing in biological medications through advanced genetics, to build generative AI models for drug discovery. NVIDIA CEO Jensen Huang believes that what he terms “digital biology” will be the

“next amazing revolution,” with the revolution already underway in fields such as genomics, cell engineering and synthetic biology.

The next frontier

On the development side, generative AI has become the new paradigm, with its significant potential to impact the entire cycle of clinical trials, from study design to patient recruitment to analyzing data. (See also Trend 7). It can also help reduce cost and accelerate clinical trials. (See also Trend 4.)

A recent article in Nature describes ways generative AI is revolutionizing clinical trials. In addition to design, recruitment and analysis, generative AI also has the potential to deliver prompts and encouragement that keep trial participants enrolled and engaged in trials, Nature notes. Recruitment and retention are well-known major challenges in getting a trial to completion.

On the analysis front, generative AI and AI algorithms can potentially process and analyze complex datasets quickly, identifying patterns and correlations that might be missed by traditional methods. This capability allows for more adaptive and flexible trial designs, where adjustments can be made based on interim results.

In addition to generative AI’s potential to propel clinical trials, it might also allow companies to develop drugs via synthetic data, or computer-generated data used as a replacement of data from humans or real-world events. In the quest to treat diseases, clinical research needs high-quality data.

As disease study grows more specific, the datasets can grow thin.

Here, generative AI applied to quality small data sets can be used to synthesize larger datasets that can advance research and treatment. Published research shows success using this approach in studying leukemia.

Augmenting existing solutions

While more modest than new miracle drugs and game-changing innovations, generative AI also augments existing processes. Solutions driven by generative AI to enhance process across pharmacovigilance, clinical trials, personalized medicine, data management and analysis, and administration significantly reduce time to market and costs.

As generative AI models are trained to detect adverse events, they can enhance pharmacovigilance. Patient reactions are analyzed using data from multiple sources to alert for issues or clinical trial complexities. Data ingestion and trend detection improve pharmacovigilance, understanding patterns that could contribute to adverse reactions.

As with the United Kingdom's NHS's success in reading mammograms, generative AI-fueled innovation extends beyond crafting novel therapeutics to diagnostic innovations. A recent study shows that generative AI can detect sepsis in patients, and Paige.AI uses generative AI to improve early detection of prostate cancer. It is the first firm to win FDA approval for the use of AI in digital pathology.

Personalized, precision medicine is another

area that directly benefits from the analytical and interpretive capabilities of generative AI. Access to vast quantities of data offers deeper patient insights, allowing for physicians, healthcare organizations, and pharmaceutical companies to create treatment plans that reflect the individuality of the patient.

Previously, it was not possible to achieve this level of personalization across a detached medical history, and at scale. Patients visiting multiple doctors across different specialties did not receive cohesive care due to fractured datasets and limited visibility.

However, generative AI through large models creates a holistic patient picture and uses that information to develop a personalized care plan for that individual. While the technology is in place, access to all this patient data is constrained by healthcare regulators (e.g., HIPAA in US, NIH in UK).

In a similar vein, generative AI organizes disparate data sources, gives structure to unstructured data, and brings together apparently unrelated information in ways that deliver new meaning.

Generative AI has the capacity to absorb and analyze data from billions of sources, so it could potentially collate data from multiple sources to extract insights, manage administration, refine patient interactions, and collect historical medical knowledge.

This is especially valuable for clinical trials. For example, data held within traditionally fractured sources such as physician notes, laboratory notes, clinical trial insights and

historical medical knowledge could be ingested and analyzed to build health and pharma intelligence.

Healthcare providers and pharma companies can then use this intelligence to personalize medicine, discover bottlenecks in healthcare or operations, and improve clinical trial outcomes.

The Truveta Language Model is a large language model designed to overcome the complexity of siloed and inaccessible healthcare data. It's being used to turn electronic health record (EHR) data into accurate data points for drug, disease, or device research. Its goal is to simplify access to data and improve patient outcomes.

Finally, within the broader generative AI category, Google has consistently worked to build a safe, consumer-focused EHR record since 2008. The company's Google Health project was shut down in 2012, but the tech giant has continued to work toward more connected health applications through the use of generative AI, including two new models launched toward the end of 2023. These focus on improving administrative

tasks and research development.

The need for guardrails

To reap any benefit from generative AI, life sciences companies must put in place guardrails that address the security, privacy, ethical, data quality, and trust concerns its existence brings into play.

Life sciences companies must address these concerns before generative AI is implemented at scale. Specific solutions are emerging to address the sector's major challenges of access to universal data and shared insights.

However, even as generative AI solutions offer "black box" solutions, they raise other thorny problems. Any generative AI data solution must answer ethical, accessibility and security questions about non-transparent and potentially biased data use that could impact patient trust and outcomes. Experts currently advocate for a glass box model that treats data ethically and transparently.

Placing humans at the center of these innovations and ethical practices provides a

“

Embedding personal generative AI assistants into everyday work processes to improve speed and productivity is not a choice of "if to do it" but rather "when to do it."

Martin Woergaard

Chief executive officer, BASE life science

”

simple yet effective guide for generative AI implementation and will create a safer path to improve patient and practitioner outcomes.


Confidence over ROI

The life sciences and healthcare sectors have struggled to realize benefits from AI, despite heavy investment. In fact, it lags other industries in return on AI investment – possibly because of the greater volume

of data that must be analyzed. Computer processing power and capacity must increase before complex conditions can be mapped and addressed with confidence. Also, healthcare data requires considerable curation before it can be used in AI models.

Generative AI provides an opportunity for life sciences to significantly increase their return on AI investment. As shown in Figure 2, chatbots currently demonstrate the

Figure 2. Life sciences leaders are confident generative AI will provide ROI in the next three years



Note. Percentages do not total to 100 due to rounding.

Source: Infosys Knowledge Institute

highest ROI for life sciences enterprises. This is not surprising, as chatbots are a mature technology, developed well before the recent wave of generative AI innovation.

Other areas demonstrate ROI as well, with sales and marketing as the most productive use cases. In fact, our research shows each area of potential generative AI-assisted innovation demonstrates some return. While this points to a positive future, prioritization and adoption challenges must be overcome to realize this potential. The area most anticipated to increase ROI in the coming years is drug, gene, and protein sequence design, with nearly six in 10 life sciences leaders saying that this area will drive returns.

Evolving law and regulation

AI legislation and regulation will be codified in the coming years, as countries take note of the 2024 EU AI Act and study its impacts. In the meantime, guidance is being formulated for the life sciences sector. In the US, the Department of Justice is concerned that the use of generative AI in health records could result in fraud or faulty recommendations, while the Office of the National Coordinator for Health Information Technology has released a draft federal health IT strategic plan that highlights the need for education and transparency around the use of generative AI.

The Coalition for Health AI (CHAI) has developed a blueprint for generative AI in healthcare, and its efforts are echoed by the Generative AI Council to Advance Life Sciences Innovation, a group of leaders from pharma, academia, and technology.

However, the industry is also wary. Our research shows that life sciences leaders are keenly aware of the barriers that hinder implementation and adoption, based on previous technology initiatives and their pervasive regulatory environment.

Half of all leaders cited legislation and/or regulatory barriers as either significant or highly significant obstacles to their use of new technologies, including generative AI. This is a looming challenge for industry leaders. Investment and innovation with generative AI are accelerating. But trust, regulation and legislation move more slowly, and are perceived as obstacles by half of life sciences leaders. This creates a gap between the confidence to invest in the tech and the confidence to use it in a legally and ethically sound, compliant way. This is particularly relevant in life sciences, where misuse, mistakes, and bias can impact on human life.

Guardrails must include accountability, ethics, awareness, transparency, and regulatory compliance at the very least. Designing these now into how organizations use generative AI, at the beginning of their journey, will embed these principles as part of responsible AI and an AI-first mindset.

Generative AI has the potential to dramatically uplift life sciences, improving R&D, engagement, and efficiency. The research insights reinforce the imperative for responsible leadership to guide this exciting technology. Enthusiastic experimentation will transition to methodical adoption. Enterprises that balance these factors can create significant value while serving patients better.



Trend 2: AI and behavioral science transform digital therapeutics

- The Covid-19 pandemic turbo-charged the emerging trend of digital therapeutics, with practitioners and life sciences leaders increasingly aware of their potential to improve access to better, more personalized treatment for a wide range of conditions.
- Digital therapeutics will surge in effectiveness and in market growth by combining AI and insights from behavioral science.
- We expect that pharma and medical device companies will continue to evaluate, incubate, promote, and include digital therapeutics to improve efficacy of existing medicines and devices, increase access to patient data across the patient journey, and strengthen brand positioning.

Advances in digital therapeutics are changing how and where healthcare is delivered, moving care from the hospital to the home. These advances augment existing therapies by tracking and promoting wellness, detecting preconditions, and monitoring and managing health conditions digitally.

This shift has vast potential to help prevent, manage, and treat diseases and conditions, potentially reducing the burden of disease and health administration costs. It also improves health equity by providing in-home treatment for hard-to-reach communities, which often have the most unmet needs,

and for groups previously considered niche — like women. Further, it has the potential to change the trajectory of healthcare for developing countries in ways uniquely suited to the geographic needs and befitting economic constraints.

Digital therapeutics help healthcare providers tailor interventions prescribed to patients and ensure compliance. For maximal effectiveness, digital therapeutics require providers to leverage insights into people's behaviors and what influences these behaviors. These insights are uncovered through a combination of behavioral science, AI, and datasets from people's social lives.

However, technology also introduces risks from device and application obsolescence and ecosystem incompatibility. These risks create additional compliance barriers when vulnerable people use unsupported devices and apps. In addition, risks of data leakage or theft increase when health technology is used outside of a clinical setting.


Rapid growth, vast potential

The rapid growth of medical technology in the past few decades has given rise to this new, digital category of therapeutic interventions. These include companion software to help treat, manage, or prevent conditions and diseases, and span technologies that include web and mobile apps, wearable and ambient sensors, virtual reality and video games. Many of these technologies are enabled by AI and data analytics delivered at the edge.

Digital therapeutics now include pills with sensors that transmit information directly to a mobile device to ensure compliance with treatment regimens. For patients with diabetes, these applications sync pharmaceutical therapies, fitness brands, and health trackers with glucose meters. Another novel product is smart contact lenses that detect glucose levels in tears.

Digital therapeutics function most effectively in combination with conventional therapies, often with the intention to improve patient adherence to treatment regimens. Digital therapeutics is a significant growth area in life sciences, with the market expected to jump from \$4.8 billion in 2023 to \$25.3 billion in 2032. With AI's rapidly increasing capabilities, market growth and efficacy stand to exponentially increase. Indeed, 94% of companies in our survey of executives from

Figure 1. Almost all companies plan to increase their spending on digital therapeutics in the next two years



Source: Infosys Knowledge Institute


top life sciences companies say they plan to increase spending on digital therapeutics in the next two years (Figure 1).

With the growing recognition that these technologies improve patient quality of life, a rich partnership ecosystem is developing among the healthcare and pharmaceutical industries, commercial companies, research entities, and technology and service providers.

Our survey asked executives to allocate 100 points to indicate investment areas among subrends enabling the increased impact of digital therapeutics. Priorities were split quite evenly (from 21% to 27%) among integration with traditional therapies, remote patient monitoring, virtual care platforms, and patient engagement and adherence (Figure 2).

These enabling subrends are also part of a broader move towards decentralized, hybridized healthcare. Virtual care platforms, for instance, provide a range of services to patients to meet them outside of the physical office and make it easier to get the care they

Figure 2. Life sciences companies plan to spend in four critical areas



Note. Percentages do not total to 100 due to rounding.

Source: Infosys Knowledge Institute

need. In Trend 4 in this journal, we discuss the benefits of combining virtual clinical trials with in-person clinical trials: improved patient engagement, experience, and adherence. For both virtual trials and digital therapeutics, remote monitoring is a less invasive way for researchers and HCPs to gather patient data.

From startup to scale

As an emerging category within healthcare, digital therapeutics is mostly the domain of small innovative firms and startup ventures.

“

Digital therapeutics increases patient adherence to protocols and improves health outcomes. It complements contemporary treatments with digital options, addressing gaps in an already constrained healthcare ecosystem.

Gurdeep S. Rooprai

Associate vice president, Infosys Life Sciences

”

But it is already very relevant to larger life sciences organizations, pharmaceutical and medical technology alike.

Here are two compelling reasons. First, startups will only achieve reach to a large number of patients with the sponsorship of large life sciences organizations. For the big incumbents, early-stage partnerships or incubator relationships smooth the integration of innovative new digital tools with established processes and systems. Second, as digital therapeutics reach scale, they will spawn more and richer data about patients and patient journeys. The large and established life sciences companies that engage with digital therapeutics at the present stage will have access to that data. Rich data then has the potential to influence patient adherence, enhance efficacy and improve patient outcomes.

AI and behavioral science

An especially promising area is the combination of AI with insights from behavioral science. For instance, an app can analyze a user's behavior and predict when to nudge them to take medication, exercise, or follow their prevention or treatment plan.


As described in Trend 4 in this journal, non-invasive monitors collect patient health data, such as facial emotions, gait patterns, and sedentary time. Similarly, data from monitors, fed back into apps, can provide highly personalized prompts and feedback to patients as well as modifications to the engagement interfaces and the health and care plans.

With rapid innovations in both AI and digital therapeutics, it is not difficult to imagine that a company will create a Spotify-like playlist for health.

Specifically, this would be an interactive, smart system that suggests a personalized series of treatments based on patient (aka user) data, in the same way that streaming services suggest playlists based on a user's preferences. This health playlist would evolve over time and according to preferences, and how a condition evolves — and also based on changes in patient behavior, mood, and environment.

A recent study explores how AI and machine learning (ML) can analyze patient engagement — the primary indicator of success of digital therapeutics interventions. Researchers showed that AI and ML can indicate not only the level of engagement but also the quality of

Figure 3. Most life sciences firms expect generative AI to provide ROI in digital therapeutics



Note. Percentages do not total to 100 due to rounding.

Source: Infosys Knowledge Institute

engagement. This and other AI applications that measure engagement and experience detect where engagement plateaus – and then automatically recommend a different approach.

The role of generative AI

It is early days for generative AI in this field, but 99% of our survey respondents expect generative AI to achieve return on investment in the next three years (Figure 3). In fact, 7% say they have already achieved returns for generative AI in this rapidly progressing field, despite the up-front tech costs and behavior changes required for patients and providers.

Generative AI is expected to improve the patient experience – perhaps ironically, as AI has the potential to make patients feel more cared for, thanks to personalization via richer, data-based feedback.

Practical benefits

Digital therapeutics products offer benefits not only to individuals and their healthcare providers but also to society more broadly.

At the individual level, these products help patients manage chronic conditions such as diabetes, autoimmune diseases, and cancer. For instance, digital therapeutics assist with managing complicated dosing requirements and self-administration of treatments as well as complementary changes in patient's well-being behaviors, such as nutrition or physical exercise. They also provide a personalized mix of educational materials, dosing guidelines, and tools for monitoring side effects.

Together, these interventions make it easier for patients to maintain medication regimes. Medication non-adherence is a common problem, with approximately 50% of patients not taking their medications as prescribed. Increasing patient compliance was identified as “the most impressive application of digital therapeutics” from a diabetologist's perspective. The Digital Therapeutics Alliance lists the benefits as increasing access to therapies; offering the convenience and privacy of home treatment; providing therapies in a variety of languages; and providing results and supplying insights on personalized goals and patient outcomes.

These benefits extend beyond the individual by improving access to healthcare and addressing disparities in care at the population level.

Digital therapeutics products equalize the rural versus non-rural health divide, providing patients “asynchronous support and therapy when they are actively experiencing symptoms or are unable to immediately access their healthcare providers.” Digital therapeutics are available or under development for six of the seven causes of death identified by the US government initiative Healthy People 2020. These products directly address the disease or underlying associated conditions and stand to substantially improve people's health.

Digital therapeutics in action

Digital products are already in use or are under investigation in several areas of the life sciences industry. For example, the complex

women's health space has traditionally been left behind, limited by data and research built on male medical profiles. As the femtech market plays catch up, it is expected to grow from \$36.5 billion in 2023 to almost \$42 billion in 2028. This growth is fueled by an increasing radical global awareness of women's health disparities, and the market will utilize multiple levers, including AI, data, crowdsourcing, and innovation to address the gender healthcare gap.

One healthcare technology company focused on improving women's cardiovascular health recently received funding to support a clinical trial for textile-based sensor technology to gather medical-grade data from women's physiology (a smart bra). The trial will address women's low participation rates in cardiac rehabilitation programs and will use a personalized, data-driven approach to improve patient experience in cardiac rehabilitation.

Despite only modest growth in 2024, global wearable technology is forecast to grow in the product areas of smartwatches and smart rings. Some analyses suggest a resurgence of interest in smartwatches, especially in emerging markets like India. These portable, wearable medical devices consolidate health data and provide physicians with immediate medical readings from patients.

An upcoming special issue in the peer-reviewed journal *Sensors* explores wearables for neurological conditions. These so-called neurological wearables offer remote assessment, testing, and treatment of neurological injuries and diseases. Wearables

capability in neurology and other clinical areas is expected to drive the market segment further, particularly in the ability to assess cognitive capabilities during everyday activities. Beyond wearables, a wave of innovation also extends to ambient sensors embedded in people's homes, enabling more continuous monitoring and avoiding the user-dependent challenges of wearables (dead battery, forgetting or simply deciding not to wear them, etc.)

Shifting from device types, companies are applying digital therapeutics to a widening range of conditions. This includes topics ranging from pain management, anxiety and depression, digestive health and sleep management to cancer treatments, respiratory therapies and treatments for neurodegenerative conditions.

Fuller implementation

Like other life sciences disciplines, digital therapeutics was catapulted into prominence by the Covid-19 pandemic. Their momentum is extending as they prove their value in multiple areas – community health, women's health, neurological conditions, more and better data, and patient experience. However, success also relies on the understanding of and compliance with an increasingly challenging regulatory landscape, and a growing imperative for trust and transparency.

Our research shows that regulatory barriers are a priority for life sciences leaders, with 49% indicating that regulations are significant obstacles to implementing new technologies.

A further 34% say this is a moderately significant barrier. For digital therapeutics, the picture is fragmented—the EU has no specific legislation on digital therapeutics. However, Germany has established its own Digital Healthcare Act, which addresses digital therapeutics.

There is a pressing need for new regulatory frameworks and to improve regulatory ability to evaluate increasingly complex products, which support rapid updates to their software and use adaptive algorithms that change over time as they encounter new data.

Other challenges include the difficulties of reimbursement through insurance, lack of development skills for those creating digital products, patient acceptance, devices that become obsolete, and technology ecosystem incompatibility, such as competing operating systems).

Despite their promise, digital therapeutics solutions have not yet fully entered mainstream healthcare. This is partly because it is difficult for patients and health practitioners to separate unproven, low-value applications from genuinely valuable, evidence-based products. Finally, as with any device that stores and transmits patient data, privacy and security are particularly important for digital therapeutics.

Another challenge for AI-based digital therapeutics will be evaluating their safety

and efficacy in diverse populations. This is crucial to ensure equitable healthcare delivery. Device labeling should clarify how AI models were trained and how they derived their outputs.

On the cusp of growth

Advances in AI continue to stir up excitement about digital therapeutics. Its acceleration depends on both expertise about software and patient behavior, and companies navigating an uncertain regulatory landscape. It also depends on trust. Like all interventions, the physician-patient relationship has long been understood as a cornerstone of good outcomes and functional health. This relationship is essential in digital therapeutics too – as is trust in technology to provide the expected medical outcomes. Especially as digital therapeutics expands into new clinical fields, real-world data and evidence is necessary for this area to reach its full potential. Digital therapeutics thus stands to benefit from the kind of collaborative ecosystem described in Trend 7 of this journal, and in research published in Nature.

Clinicians, academics, commercial companies, manufacturers, regulatory bodies, and organizations like the Digital Therapeutics Alliance can together overcome implementation and engagement barriers. These collaborations can also lower costs, as well as historical healthcare bottlenecks and complexities.





Trend 3: From traveling salespeople to digital feedback loops: The future of life sciences sales and marketing

- The shift to virtual engagements driven by the pandemic has increased flexibility for healthcare sales professionals, freeing up their schedules by balancing in-person and remote interactions.
- Digital tools lead to better insights and a continuous feedback loop that allow sales reps and healthcare providers to choose the most effective ways to interact with each other, although some providers still struggle with the learning curve inherent in new technologies.
- We expect that companies that meet healthcare providers where, when, and how they want will have a tremendous competitive advantage — in large part because the digitalization of these interactions creates more touchpoints and more data.

Sales and marketing relied on virtual solutions during the pandemic to connect with healthcare practitioners, and to build and maintain relationships. And this door remains open. These practitioners now accept virtual interactions with sales and marketing agents as a viable option that

complements, rather than replaces, face-to-face meetings. Organizations discovered that virtual platforms improve customer engagement through synchronous and asynchronous communication channels and meet physicians at their points of need — first multichannel and then omnichannel.

This can reduce the time burden for practitioners and sales representatives; improve sustainability through reduced travel; increase reach and opportunities through digital channels; and support the shift toward a service model. In addition, healthcare professionals can more easily bring sales reps into discussions than with in-person meetings.

Most companies have returned to face-to-face interactions, rather than seeking the optimal mix of live and virtual engagements that leads to the greatest impact. But the potential to use digital technology for sales and marketing goes beyond virtual agents. The growing number of data points derived from chatbots and other digital assistants creates a feedback loop to make better decisions, whether it's a whisper agent, agent assistant on a call, or simply providing sales with better insights on each individual provider. However, teams must be structured in ways that ensure the data is analyzed and used, or its value may be lost.

Companies are just beginning to realize the potential for remote sales and marketing. For instance, AI can enhance traditional customer relationship management (CRM) systems to automate tasks, gain insights from large datasets, and provide more customized experiences. When combined, these solutions allow businesses to offer more support and better access to products and solutions, and to reduce practitioner time requirements.

While automation is important, it is not the only goal. To succeed, CRM platforms need to evolve from transactional proof

of interactions to managing customer relationships and experiences — a true customer relationship management solution. Organizations will benefit by moving beyond compliance systems to something more valuable for all stakeholders.

From travel to virtual

Life sciences sales reps have traditionally been at home in the waiting rooms of healthcare providers (HCPs), expecting to develop one-on-one relationships. In 2020, just before Covid-19 became a pandemic, 75% of physicians said they preferred on-site visits from their sales reps, compared to remote interactions — but a year later, nearly half preferred virtual exchanges. Data from 2023 indicates a stronger preference for face-to-face, one-on-one visits (43% for male and 38% for female healthcare professionals).

Necessitated by lockdowns, lightning-fast innovation accelerated remote technology and allowed sales reps to move beyond their traditional relationship-based philosophy and ensure they added value to the healthcare providers. In the process, this digital approach — focused on customer experience — increased the number of touchpoints. Successfully orchestrating large numbers of customer touchpoints improves the transaction and adds tremendous value to the long-term relationship value.

In the past few years, sales reps have found that they could meet healthcare providers on their terms, while ensuring that their relationships remained intact and resources accessible. Half of physicians now prefer

totally or primarily virtual engagements, compared to 20% pre-pandemic, according to research from Bain & Company. The preference for virtual engagements is even higher (80%) among healthcare administrators, an increase from 33% before the pandemic.

This move away from in-person interactions is just one element challenging sales and reminding life sciences companies that they need to center the preferences of the providers. Even before the pandemic, about 40% of physicians refused to see sales reps at all, and the numbers remain high. The factors for not wanting to meet reps include physicians switching from independent practitioners to health network employees, mistrust of content supplied by life sciences companies, and not wanting to take time away from patients. And so some HCPs are already shifting their scheduling priorities toward medical science liaisons rather than sales representatives.

Post-pandemic burnout — partly created by overwork, but also by administrative burden — continues to be a problem in the healthcare field. Burnout is likely another

reason physicians do not want to meet with sales reps. A US survey of women in healthcare, including physician assistants and technicians, found that 86% had experienced burnout. And nearly two thirds (64%) said they were at risk of burning out, which is often influenced by workload. A US federal survey of healthcare workers found that having enough time to do their jobs was an important factor in reducing burnout.

With a wide variety of interactions now possible, the outlook can be confusing. Physicians are reluctant to meet with sales reps and often prefer remote communication. Healthcare workers weigh the value of every interaction or activity that takes time away from patient care. However, 100% virtual visits are history and can often be limiting — despite the time benefits. Meanwhile, sales reps prefer in-person meetings for their tremendous value to develop and maintain relationships. Both sides have to give an inch, or more, to engagement channels at the right time. Then engagement type, whether advisory board or sharing of product launch data, should determine the channel. And for life sciences companies, using data to determine the optimal will be critical

“

Companies must build a service engagement model for their team to continuously add value to HCPs, and the technology should support this path.

Luca Morreale

Chief commercial officer, BASE life science


”

as they pivot from a multichannel to an omnichannel approach.

For the life sciences industry, this balancing act in sales and marketing is critical to their future interactions with clients, and also their spending plans. To support this kind of omnichannel e-detailing, virtualization remains a significant investment priority in life sciences: 25% of industry leaders say they plan to invest between \$10 million and \$50 million in sales and marketing virtualization between now and 2026. An even larger percentage (75%) expect to significantly increase these investments in the next five years.

As life sciences companies seek to balance the virtual and in person, it is often easy to focus on productivity. While that is valuable, impact must remain the most

Figure 1. Nearly three-quarters of life sciences leaders plan to increase investment in virtualization of sales and marketing in the next five years



Source: Infosys Knowledge Institute

important factor and can be enhanced by small changes. Interactions between the commercial organization and the medical organization, rather than a siloed approach, tend to bring better results. Adding the market access function to the mix will ensure the coverage of all relevant topics while serving the needs of the HCPs.

Benefits of digital engagement

Two-thirds of biopharma sales leaders say they already employ an even mix of virtual and in-person engagements. This hybrid approach is clearly the future, but developing the right mix — and the right timing of the mix — will be more difficult than anticipated.

Phil Benton, partner in AI experience transformation at Infosys Consulting, says that sales leaders need to consider which in-person engagements are better virtually, and how these vary by product lifecycle and physician specialty. For instance, when a product launches, Benton suggests that virtual engagements are best to maximize short-term reach, when HCP interest in the product is high.

Virtualization and other emerging technologies require companies to upgrade their data and analytics strategies and practices. Life sciences businesses can use advanced analytics to gather raw data from digital interactions. That data generates valuable insights, such as measuring engagement levels and identifying which interactions lead to sales. These insights help sales and marketing teams to explain products, sell solutions, and resolve queries.

This feedback loop enables continuous improvement and enhances the impact of sales and marketing efforts, particularly when the focus is more on the customer than the product.

In addition, AI augments traditional CRM systems by automating tasks, gaining insights from large datasets, and providing more customized experiences. With the right data, analytics can direct sales and marketing leaders toward determining the best time to make an in-person visit versus scheduling a virtual meeting, how to best optimize each approach to suit specific individuals' needs, and how to plan proactively instead of reactively. Even in situations where some interactions are by their nature reactive — for example, with medical science liaison visits — reps can still plan messages that should be shared in those interactions.

Freeing up time from travel schedules allows reps to spend more time on improving the quality of their interactions and focus less on the frequency.

Generative AI to connect dots

The search for the right hybrid balance has arrived at a fortuitous time. The need for technology solutions coincides with the rise of generative AI. When life sciences companies gather all the data they need on marketing and sales efforts, generative AI will allow them to connect the dots more quickly and effectively.

The mix of data needs to include information about events, industry news, market access


efforts, and competing products, especially in specific therapeutic areas. In addition, companies need to include patient data, although outside of the US this is difficult since only proxy data is available. Based on all those data points, you can define the right market mix. "Continuously reviewing your marketing mix model through the lenses of AI to improve the impact could deliver tremendous value and ensure the right message reaches the right HCP at the right time," says Morreale.

Our survey indicates that generative AI is now delivering ROI for life sciences sales and marketing more than in other areas of the value chain (see Trend 1). Further, four out of five sales and marketing use cases we surveyed achieved ROI for at least 20% of respondents — compared with less than 5% for some use cases in supply chain and manufacturing (Figure 2). Chatbots for patients was an outlier, with nearly 50% of respondents saying they already achieved ROI. The survey did not ask about chatbots in sales and marketing, however.

Generative AI-powered segmentation is an area rich for exploring faster, more efficient, and more granular divisions of customers into different brackets based on specific characteristics. For example, the Veeva Pulse Field Trends Report determined how often various specialties meet on average with reps. Understanding these demographic trends can only help drive better engagement, although delving further into behavioral segmentation can offer greater value.

Data from each company's interactions

Figure 2. Generative AI returns positive ROI in sales and marketing in four of five use cases



Source: Infosys Knowledge Institute

might offer different insights or additional nuances particular to a specific field, region, or types of products. Proprietary data can fine-tune messaging, hone interactions, create customized engagements across digital and physical platforms, and improve personalization.

Our research has found that life sciences executives prioritize data-driven personalization as their top investment priority in sales and marketing efforts (Figure 3). Even so, approvals remain a challenge as even advanced companies still struggle with medical, legal, and regulatory bottlenecks.

Moreover, data created by virtual tools and other emerging technologies — especially those powered by generative AI — can institutionalize knowledge that might disappear when a longtime rep leaves the company or the industry. These tools ensure that information about specific HCPs, companies and products remains within the firm and ensures valued relationships remain intact. This type of knowledge drain


is a concern in many industries, including life sciences.

Digital solutions address these challenges by ensuring that behavioral analysis is taken from data and not solely from the rep's input. However, many enterprises struggle to adopt these tools, which can hinder progress. Companies need to ensure that each tool is suited for its specific need.

Although these solutions are technology-oriented, the core element of sales is the relationship. Virtual tools and solutions offer significant benefits, many of them cost savings.

But the value of authentic, in-person engagements cannot be overlooked. Building connections based on integrity and transparency is essential, particularly as it relates to trusting new technologies. We have focused our discussion of the sales and marketing virtualization trend on 1:1

Figure 3. Life sciences leaders prioritize data-driven personalization investments



Note. Percentages do not total to 100 due to rounding.

Source: Infosys Knowledge Institute

meetings between physicians and sales reps, but events are also a tremendous opportunity to mix in-person and virtual modes.

How to persuade physicians

To be more successful, reps can engage with HCPs on their attitudes toward technology, particularly those customers who were traditionally technology-averse. The past tense is key here. While some physicians remain resistant to technology encroachment, a recent AMA survey found that many are open to use cases, particularly around AI.

Virtual meetings, generative AI, self-service chatbots, and data and analytics tools offer opportunities to ease medical professionals into additional technologies and help them overcome their hesitancy, so this should be approached on a case-by-case basis, while ensuring that physicians are given the information they need to feel informed and aware.

Technology is also a valuable tool in the competition for talent and to retain the top talent. The 2022 Sales Happiness Index found that 33% of sales professionals leave because they do not have the tools and technology necessary to perform their jobs efficiently.

In addition, companies that struggle to attract top talent can invest in technology as an advantage over larger or better-known competitors. “Leveraging techniques such as gamification could be a very efficient way to ensure team motivation and adoption of the business process for an optimal customer

engagement,” says Morreale. “You can engage your team internally to maximize the external engagement.”

Sales reps in the medical field remain in their roles for one to two years, according to research from both Zippia and Hubspot. Reps are expensive to replace and keeping them engaged is critical for company efforts to reduce turnover.

This rapid turnover is especially damaging if sales reps take their customer relationships with them; healthcare professionals might be resistant to form a relationship with a new sales rep.

In addition to retention issues, the life sciences industry must contend with a skills gap created by the rapid advancement of technology. Our survey found that 61% of life sciences leaders say that lack of skills in the workforce posed a significant or highly significant obstacle to realizing the benefits of emerging technologies. This was the most significant barrier for life sciences organizations’ efforts to benefit from new technology.

Compounding this skills issue is the potential for a knowledge drain as employees leave the industry or retire; 71% of sales reps in life sciences are 40 or older.

Generative AI offers new and creative options to combat this loss by collecting and passing on knowledge from more experienced reps to new ones. “The wealth of knowledge of very experienced sales representatives is the perfect input data for an AI model that trains

the next generation of reps more effectively, more quickly,” Benton says.

Tech to enhance relationships

The success of sales engagements typically comes down to building meaningful relationships and the provision of timely, valuable inputs that provide HCPs and decision-makers with the information and support they need. The balance between physical and virtual is keenly felt in these relationships, as reps use digital tools to enhance their engagements through personalization and segmentation. At the same time, they offer customers access to immediate information and support.

By providing accessible data and information to physicians quickly, reps enable them to make better, more informed decisions. It improves access to information and removes the irritation of engaging in a transactional sales approach — feeling “sold to.” Instead, life sciences companies can create a system of shared information and insights that feed

back into the enterprise customer platform to nurture relationships, trust, and transparency.

Companies need to ensure that their sales staff stay current on how these emerging technologies affect their fields of specialization. Investment in talent is required for reps to realize the benefits of new technologies and share and promote that knowledge across their organization.

The human touch and personalized support have always been a cornerstone of effective sales relationships, and particularly important in health orchestration. Leaders must not lose sight of this in the face of virtualization, AI applications, and digital transformation.

As emerging technologies become integrated into everyday life, ensuring that the humans who use them are confident and capable of using them well is crucial. Empowered hybrid sales and marketing teams will convert the increasing investment life sciences leaders make in virtualization into improved customer relationships.

“

The wealth of knowledge of very experienced sales representatives is the perfect input data for an AI model that trains the next generation of reps more effectively, more quickly.

”

Phil Benton

Partner, AI experience transformation, Infosys Consulting



Companies are increasingly exploring virtual trials as a path to reduce drug time to market, an even greater imperative as drug development costs have spiraled into billions of dollars. Virtual trials can reduce

patient dropout rates, accelerate enrollment, and increase data collection. A variety of technologies enable this trend, including telemedicine, wearables, and biometric sensors. Virtual clinical trials also improve

health equity by increasing access to a broader and more diverse patient population and providing researchers with richer data.

However, the need for in-person clinical trials persists because technological inefficiencies and talent shortages impede the ability to scale virtual trials – and patients will also want to see the doctor in person. Many practitioners lack the technology proficiency to conduct virtual trials, and they do not trust these outcomes as much as in-person trials. Initial virtual trial setup is often more expensive than for traditional trials, though speed to market and other factors do offset these costs. Additionally, many trial designs do not translate well to virtual models, such as for patients with Alzheimer's disease.

Hybrid models combine virtual and in-person trials and can optimize outcomes and reduce costs. Technologies including AI improve hybrid trials by detecting, analyzing, and improving patient clinical trial experience. For example, AI tools can analyze not only patient voice content but also their expressions and tone of voice. This behavioral data, combined with other datasets on factors like social determinants of health, improves the richness of data and, potentially, health outcomes.

Enhanced patient experience

Elements of modern clinical trials have existed for centuries. However, the gold standard of randomized controlled trials only dates to the 1940s. After decades of fine-tuning these processes, researchers are again discovering new ways to advance medical knowledge, reduce suffering, and save lives.

Traditionally, clinical trials have been conducted at hospitals, laboratories, and other centralized locations — all under the watchful eyes of medical professionals. This approach has generally served researchers well. However, it is time-consuming, expensive, and limits the trials' potential population, a primary research challenge.

For the past decade or so, researchers have experimented with virtual trials that allow participants and physicians to engage in trials from any location, with data collected and collated digitally. Remote patient monitoring, wearable devices, artificial intelligence, and other virtualization tools allow life sciences companies to create remote clinical trials that can be as effective as, and in some cases more effective than, conventional trials.

Virtual clinical trials leverage digital technologies across the clinical trial process, from design to patient recruitment to analysis and sponsor reporting. Some technologies enable continuous monitoring using wearables, sensors, health monitors, and even ingestible devices that provide practitioners near real-time visibility.

Unlike traditional trials conducted at bricks-and-mortar research facilities, virtual trials allow remote participation in studies using telemedicine and digital health tools. "Virtual trials aim to make clinical research more patient-centric and inclusive," says Ian Storr, associate partner, health and life sciences R&D lead, EMEA, Infosys Consulting. (See Figure 1 for a summary of critical differences between traditional and virtual clinical trials.)

Figure 1. Differences between traditional and virtual clinical trials

Feature	Traditional clinical trials	Virtual clinical trials
Location	Conducted at fixed physical sites	Site-less: Participants engage remotely from any location
Participant access	Geographically limited	Geographically open
Data collection	Periodically, through in-person visits to trial sites	Continuous and real-time
Patient engagement	In person	Remote and digital
Cost	Higher operational costs	Lower operational costs
Regulatory acceptance	Established	Evolving

Source: Infosys Knowledge Institute and Infosys Consulting

Virtual trials have several advantages over traditional trials. First, they are less invasive. Use of sensors in these remote trials can collect minute details such as patterns of patient movements, gait, pace, chest expansion while breathing, steadiness, and so on – all without the patient having to manually record and share that data. A patient just needs to be within a reasonable range of the device that’s in their house, according to David Champeaux, lead partner, health and life sciences, EMEA, Infosys Consulting.

The sensors that virtual trials use provide more and better data that is less prone to bias. This creates an environment conducive to better insights, thanks to continuous monitoring that extends into real-world settings. Data collected in this manner is more accurate and comprehensive. This is data that would not be otherwise captured, and is continuous, rather than only capturing a single reading at a point in time. Finally,

virtual trials increase diversity and inclusion – in the sociodemographic sense, but also in that they can include geographically diverse participants, such as those with rare diseases.

“Neither patients nor investigators of rare diseases are concentrated geographically. A hybrid clinical trial design requires the patient to visit the investigator site only periodically, greatly reducing the time and travel burden,” observes George Hunnewell, senior vice president and general manager, US, BASE life science.

Researchers have long struggled to create trials that balanced people of various ethnicities, ages, genders, and income levels. The US Food and Drug Administration’s 2015-2019 Drug Trials Snapshot found that only 7% of trial participants were Black, slightly more than half their percentage in the overall population. Hispanic residents in the US were also underrepresented, while white and Asian residents were overrepresented.

Champeaux notes the importance of identifying and enrolling a diverse group of patients into trials and to connect additional datasets during clinical trial research. Beyond information from electronic health records, these datasets will help researchers understand social determinants of health, broader social context, and life experiences.

Start-up costs are a hurdle

For many the entry point to these virtual trials has been driven by cost. In the US, clinical trials account for about 40% of research and development costs. Researchers found that because of recruitment challenges, more than one fifth of some medical trial categories end early or are closed. Approximately 80% of trials are delayed, at significant cost against expected regulatory filing commitment. The cost of these challenges adds up quickly for life sciences companies. In the US, organizations spend about \$6,500 to recruit each patient for a study, and dropout rates often top 30%. When researchers must replace a person for noncompliance, the cost to recruit a new patient averages \$19,533.

Cost–benefit analysis shifts

Despite the steep initial cost, the life sciences sector is investing heavily in virtual trials, establishing a clear trajectory toward adoption, powered by manufacturers and capital markets. The market was estimated at \$8.6 billion in 2023, with an anticipated compound annual growth rate of 7.1% from 2024 to 2032.

Although virtual trials are expensive to start, one of their key advantages is that they reduce the length of clinical trials – reducing the cost of trials. According to one study, the virtual clinical trial can bring down the median duration of the trial from 16 months to four months. Experts estimate that virtual trials reduce study costs by 25%.

With advancements in AI and generative AI, especially its ability to handle data, the cost-benefit analysis of implementing virtual trials will shift. This will lower the cost of clinical trials for companies. Life sciences companies are likely to further increase their investment in virtual clinical trials in the next five to seven

“

Neither patients nor investigators of rare diseases are concentrated geographically. A hybrid clinical trial design requires the patient to visit the investigator site only periodically, greatly reducing the time and travel burden.

George Hunnewell

Senior vice president and general manager, US, BASE life science


”

years, with the goal to reduce clinical trial cost from the current 40% to 50% of the overall R&D investment. In our estimate, the increase is expected to contribute approximately 24% to the overall projected growth in the expenditure of clinical trials market over the next two years (Figure 2).

Our research backs this up as well. Analyzing our survey data and data from other proprietary and public sources found that companies are currently increasing spending in virtual clinical trials. Our conservative estimate anticipates the virtual clinical trials to increase by nearly \$1.5 billion in the next two years, with average increase of \$750 million each year (Figure 3). This huge investment will most likely come from the largest revenue companies (greater than \$10 billion).


We also surveyed several subrends supporting hybrid trials (Figure 4). Of the investment options covered, the highest priorities were decentralization and data-driven patient centricity. However, the distribution for the top four priorities was

Figure 2. Virtual clinical trials market expected to increase over the next two years



Source: Infosys Knowledge Institute

Figure 3. Virtual trials to increase by nearly \$1.5 billion in the next two years



Source: Infosys Knowledge Institute


tight, with virtual agents and diversity in trials following with slightly lower priority. Home-based clinical services stood out as the lowest investment priority investment area.

Our further research indicates that the pharmaceutical industry is committed to increasing diversity and inclusion in clinical trials. In 2022, a multi-institutional study of 32,000 people in the US who participated in new drug trials in 2020, only 25% were Black (8%), Asian (6%), or Hispanic (11%) — compared with the 40% these ethnic minority groups comprise in the US population. This disparity is relevant because social determinants of health — everything from age to ethnicity to geography to environmental conditions — affect the way people experience a disease.

Looking ahead: AI innovations

Technologies are evolving to support this changing field, providing the life sciences industry with innovations designed to simplify, enhance, and even transform

Figure 4. Life sciences firms prioritize decentralized trials and data-driven patient-centricity



Note. Percentages do not total to 100 due to rounding.

Source: Infosys Knowledge Institute

clinical trials. In the next phase of virtual trial development, AI is expected to shape how medications and treatments are created, tested, and approved. Generative AI will enable companies to better understand the patient experience — a perennial challenge in clinical trials.

Anne Bichteler of Infosys Consulting describes a virtual trial scenario where AI-enabled voice companions accompany patients throughout their day, asking them how they are feeling and reminding them to perform critical steps to adhere to trial protocol. Then this data and face-reading technology detect and analyze sentiment, providing insights into how people physically experience a clinical trial.

When practitioners have access to these nonverbal messages, they can pinpoint early signs that a patient is considering dropping out and suggest solutions.

In addition, Bichteler says that natural language processing and sentiment analysis

can predict patient adherence to protocols, dropout, and later behaviors.

Combined with behavioral science expertise, researchers can adapt trial elements to provide a frictionless patient experience. Technology can also reinforce positive behaviors and improve patient experience, engagement, and attrition.

Life sciences companies are also tapping into the strengths of machine learning to find patients for clinical trials. Amgen, Bayer, and Novartis are training AI to scan health records, prescription data, and insurance claims to locate patients quickly and accurately. Virtualization dramatically increases the patient population, so AI is a natural fit to digest this volume of data. If algorithms are designed well, this approach also decreases the risk of physician or researcher bias.

In addition, generative AI can be used to normalize electronic health records data that is unstructured and difficult to parse. The Truveta Language Model transforms electronic health records into clean, accurate data that researchers and physicians can use to improve patient care and trial outcomes.

Results are already promising. In our survey of life sciences leaders, 19% say that AI or generative AI is currently generating returns on their investment in the virtualization of clinical trials.

Another 40% say that it will achieve ROI within the next three years. And a large majority (80%) say the technology will or probably will achieve ROI in trial virtualization

in the next three years. These developments not only benefit companies but carry implications beyond virtual trials. Wearable or ingestible devices designed for remote patient monitoring can be adapted for use across digital therapeutics. (See Trend 2.)

Challenges for virtual trials

Although virtual trials offer significant benefits, they also demand more from patients in some ways and create new challenges while they attempt to solve existing ones.

In both in-person and virtual trials, researchers must train patients to meet trial expectations, such as dosing compliance and data collection, and minimize errors that result from unfamiliar devices or medication protocols. Patients need comprehensive training to ensure they clearly understand instructions and avoid actions that skew the results. Researchers must provide patients with regular reminders of study rules.

Virtual-only trials also risk creating new biases. Groups less comfortable with technology—older people and others that are less tech savvy—might not participate. To take part in a virtual trial, participants must learn and engage with the platform and perhaps new technology. They might have low confidence in the technology and not trust that their data is secure and private. In these cases, the tools empowering virtualization become a barrier to entry or increase the likelihood that patients will drop out.

The distancing effect of technology might

cause patients to be more candid, while the lack of human interaction might make it easier for others to quit. One-on-one interaction gives physicians and researchers greater ability to answer questions and reassure patients about their concerns.

Life sciences companies also must contend with talent shortages and lack of training, making it more difficult to begin and scale virtual trials. As a result, companies could struggle to get launch trials, and outcomes could be questioned due to technical mistakes from researchers and patients.

To overcome these challenges, trials should prioritize training, increase transparency regarding biases and limitations, and build trust with participants. Virtual participant support networks are a mechanism to share information and experiences.

Communication between researchers and patients will mitigate attrition, and support network communications should occur at each stage of the research cycle. Fortunately, the virtualization model enhances ongoing communication.

An effective hybrid approach

Virtual and in-person trials each present complexities and challenges, yet they are an opportunity to create a more effective hybrid approach. Blending in-person engagement and digital interactions creates a trial environment that supports both patient and practitioner needs, while reducing the drawbacks of each. This hybrid approach is particularly valuable in high-risk trials, or

for complex procedures. A mixed model also helps reduce dropout. Combined with behavioral science, generative AI analytics, and access to broader datasets, life sciences companies can develop hyperpersonalized trial experiences.

As barriers to entry are removed, patients are more likely to engage with the trial and enabling technologies. Tools such as wearables and smart devices are unobtrusive and aid patients to stay on track. These tools minimize forgetfulness, improve adherence to trial expectations, and deliver monitoring data to physicians — removing much of the administrative burden on the participant.

Virtual clinical trial technologies help life sciences organizations improve trial patient identification and enrollment and create more diverse cohorts.

However, this requires connecting more datasets, developing insights from multiple sources, and moving beyond electronic health records. Data must include social

determinants of health, gender, and broader social contexts.

This technology enhances data quality, access, and insights and supports removal of inherent biases. Generative AI-driven systems automate the patient identification process, which in turn reduces the burden on physicians and mitigates the risk of bias by selecting patients based on established criteria instead of preconceived ideas. As with other initiatives since the end of the pandemic, the initial rush to fully remote methods to conduct trials has since given way to a hybrid approach, which combines the benefits of in-person interaction with the scale and reach that technology can deliver.

However, hybrid and the rollout of technology bring their own issues. These include ensuring that data is used ethically and that robust governance is in place, and that care is taken to address issues of properly informed consent among patients who might be less familiar with the technologies being used by the trial organizers.

“

Virtual trials aim to make clinical research more patient-centric and inclusive.

Ian Storr

Associate partner, health and life sciences R&D lead, EMEA,
Infosys Consulting

”



The answer lies in the convergence of intelligent manufacturing and visionary leadership beyond machines and materials: Reinvalidate the operating model, elevate

humans in the age of AI, and aggressively leverage technology breakthroughs.

To unlock and create value, even a visionary manufacturing strategy requires an operating model that is up to the task. Business functions are moving to scalable platforms, corporate capabilities are shared across the industry ecosystem, and technology advancements have created step-function performance improvements.


Network orchestration, talent upskilling, and rapid learning models have taken their place as essential components of the

modern pharmaceutical operating model. This chapter examines how pharmaceutical manufacturing can unlock value now while taking steps to realize a vision of operational excellence for the rest of this decade.

A vision for manufacturing

How might the manufacturing operating model look? We see a profound shift toward intelligent, agile, and sustainable production operations. The smart factory is already on the rise: The global smart manufacturing market is expected to increase to \$650 billion by 2029, from \$277 billion in 2022.

Figure 1. Pharmaceutical manufacturing operating model



Source: Infosys Knowledge Institute

Beyond operational performance, manufacturers have an opportunity to revolutionize the way drugs are produced and delivered to patients worldwide. Through emerging manufacturing methods and enabling technologies, companies can achieve new levels of productivity, quality, and compliance (Figure 1).

Personalized medicine

Utilizing advanced analytics and genetic profiling, manufacturers will tailor therapies to individual patient needs, optimizing efficacy and minimizing adverse effects. This shift toward precision medicine requires flexible manufacturing processes capable of producing small batches of customized treatments at scale. For example, the US Food and Drug Administration (FDA) has approved several drugs tailored to genetic mutations, such as pembrolizumab for patients with certain types of tumors with specific biomarkers. Initiatives such as the US federal Precision Medicine Initiative promise to accelerate the adoption of personalized medicine, largely through the collection and analysis of medical data.

Advances are also occurring in precision therapies such as CAR-T (chimeric antigen T-cell receptor) treatments, which are tailored to individual patients. These breakthrough gene therapies treat or cure genetic diseases, diabetes, and blood disorders. A study of 54 patients with hemophilia B found that 51 did not require prophylactic treatment three years after being treated by gene therapy.

These drugs are manufactured in small batches and to the highest safety and accuracy standards. However, the cost of these therapies has limited their potential so far. In the US, CAR-T therapy costs \$400,000 per dose, largely because of manufacturing costs. Other gene therapies can cost as much as \$4.3 million per dose. Fortunately, Indian pharma company ImmunoACT is manufacturing a new CAR-T therapy called NexCAR19 that is expected to cost \$50,000, an encouraging step to make these treatments more widely available.

Digital twin technology

Digital twin technology is revolutionizing pharmaceutical manufacturing by enabling

“

Intelligent manufacturing will help bring flexibility in manufacturing, better quality, improved productivity, and provide customization at scale. It will allow companies to produce personalized medicines at much higher quality.

Prabhat Kaul

Vice president, Infosys Life Sciences

”

virtual experimentation and predictive modeling. Manufacturers simulate production processes in real time, optimizing parameters and identifying potential issues before they occur.

Virtual manufacturing environments serve as testbeds for innovation, accelerating the development and deployment of new drugs and formulations.

Pharmaceutical companies leverage digital twins to simulate production processes, optimize equipment performance, and predict outcomes. For example, Sanofi used virtual twins to simulate manufacturing systems prior to implementation and to refine production processes before deploying them. This enabled Sanofi to accelerate the timeline to launch its new vaccine manufacturing plants.

Continuous manufacturing

Traditional batch-based manufacturing will give way to continuous manufacturing systems that offer new levels of efficiency, flexibility, and cost-effectiveness. Continuous processes will enable real-time monitoring and control, reducing time to market and minimizing waste. By integrating upstream and downstream operations, manufacturers will streamline production processes and enhance product quality and consistency — vital for new precision medicines.

Pfizer, Vertex Pharmaceuticals, and others have implemented continuous manufacturing processes for some drugs, reducing production time and improving

product quality. Experts also predict that switching to continuous manufacturing plants will decrease production facility size by as much as 70%.

Regulatory agencies are also encouraging the adoption of continuous manufacturing through initiatives like the agency's Emerging Technology Program. Research into continuous manufacturing in the US found no significant regulatory barriers, and the accelerated time to market provided an estimated \$171 million to \$537 million in additional revenue for pharma companies.

Data-driven decisions

Data is at the heart of pharma manufacturing, driving informed decision making and process optimization. Large language models will come and go, but enterprise data and knowledge will always be valuable. Advanced analytics and machine learning will unlock insights from vast datasets, meaning manufacturers can enhance productivity, quality, and compliance.

Data-driven decision making will lead to innovative business models:

1. Dynamic supply chain orchestration.

Companies use real-time data and AI to optimize their supply chains, allowing them to adapt rapidly to market changes and minimize disruptions while reducing inventory costs.

2. Real-time demand-supply optimization.

The new model enables “buy anywhere, ship anywhere” for

distributors, providing a consistent customer experience, optimizing warehouse resources, and boosting sales team productivity.

Companies such as Merck and Novartis have invested in data analytics platforms to analyze manufacturing data, identify trends, and optimize production processes.

Regulatory innovation

Regulatory agencies will embrace agile and risk-based approaches to oversight, fostering innovation and accelerating time-to-market for new therapies. Collaborative frameworks and regulatory sandboxes will allow manufacturers to pilot emerging technologies and novel manufacturing processes in a controlled environment.

Regulators will prioritize patient safety while fostering a culture of innovation and continuous improvement within the industry. The European Medicines Agency has already created an Innovation Task Force. This will “invite anyone with a new idea to come to us, talk about it and we try to advise as to what the right path is,” says Emer Cooke, the agency’s director general.

In addition, the FDA’s Quality Metrics Initiative advises companies on how to measure and improve manufacturing processes and product quality. Regulatory sandboxes, such as the FDA’s Digital Health Software Precertification (Pre-Cert) Pilot Program, provide a framework for piloting innovative technologies in a way that complies with regulatory frameworks.

Robust frame for innovation

To realize this vision, companies must take full advantage of emerging pharmaceutical manufacturing technologies, such as generative artificial intelligence (AI), the internet of things (IoT), advanced analytics, and cloud computing.

Growth in these areas is significant; the industrial automation market alone is projected to be worth \$115 billion by 2025. Companies already spend heavily on nanotechnology and industrial robotics, with both areas growing at a rapid pace.

The UK’s Centre for Process Innovation is working with pharma giants to create a cloud-first factory at its Medicines Manufacturing Innovation Centre in Scotland.

The public–private collaboration plans to use emerging technologies to reduce the operational cost of pharmaceutical manufacturing by as much as 30% and increase productivity by 50%.

Each emerging technology augments one another, creating not just a foundation for smart manufacturing but also a robust frame to build upon.

Generative AI drives advances

Generative AI algorithms will revolutionize drug discovery and formulation by generating novel molecular structures and predicting their properties. Machine learning models will analyze datasets of billions of chemical compounds, accelerating

the identification of promising drug candidates and optimizing formulation parameters. Analysts project that AI in drug manufacturing will grow at a nearly 46% compound annual growth rate to reach \$20.8 billion by 2028.

Generative AI algorithms are revolutionizing drug discovery and development by accelerating the identification of promising drug candidates. For example, companies such as Atomwise and Insilico Medicine use AI algorithms to design novel molecules with desired properties, expediting the drug discovery process. Furthermore, collaborations between pharmaceutical companies and AI startups are becoming increasingly common, highlighting the industry's interest around AI in drug discovery and manufacturing.

IoT devices to connect data


Biomanufacturing processes are complex,

making it difficult to implement robust analytical control infrastructure. IoT devices are ideal for connecting contemporary physical-world data with the infinite data storage and processing capabilities available in the cloud.

For example, companies such as Pfizer and GSK use IoT sensors to collect data on temperature, humidity, and pressure in manufacturing facilities, enabling real-time monitoring and control.

Infosys Knowledge Institute research found that IoT was a top pharma investment priority (Figure 2). Platforms such as PTC's ThingWorx provide connectivity and analytics capabilities tailored to the pharmaceutical industry. Beyond optimization and product quality, IoT-enabled packaging and labeling tracks inventory across manufacturing, transportation, and storage. IoT devices enable monitoring of equipment performance, reducing unplanned shutdowns and production issues.

Figure 2. IoT and connected devices are top investment priority in life sciences



Note. Percentages do not total to 100 due to rounding.

Source: Infosys Knowledge Institute

For example, Novartis uses IoT and AI for predictive maintenance to reduce downtime in their supply chain.

Additionally, IoT devices will be valuable for regulatory compliance. The data collected will support compliance by tracking conditions throughout the manufacturing process.

Data integration

The pharma industry has not made the most of supply chain collaboration thus far, but as contract manufacturing drives more advanced collaboration models, data integration and interoperability will make collaboration and information sharing across disparate systems and stakeholders easier.

Open standards and interoperable platforms enable secure data exchange, boosting innovation and collaboration. Efforts such as the Pharmaceutical Supply Chain Initiative promote data sharing and interoperability standards among pharmaceutical companies and suppliers.

Enterprise software has a role to play as well, as platforms like SAP's Integrated Business Planning for Supply Chain enable data integration and collaboration across partners.

Essential cybersecurity

No matter how attractive the potential benefits of collaboration, cybersecurity measures will be essential to protect manufacturing operations from threats and to ensure data integrity and confidentiality.

Cybersecurity in operational technology is a challenge for every industry. Legacy devices, embedded proprietary software, and 24/7 operations make managing security a challenging task.

In pharmaceuticals and medical device manufacturing, managing these challenges properly is even more important thanks to the higher regulatory requirements attached to sensitive personal information and the concurrent risks to patient safety and personal information. Cybersecurity measures include encryption, access controls, and intrusion detection systems to ensure privacy and integrity for data assets. Valuable data ranges from intellectual property worth billions of dollars to personal medical information.

Concerns about cyberthreats have discouraged some pharma companies from pursuing advanced technology — fearing that each new element increases the attack surface. Some pharma firms have avoided digital twin technology, worrying that digital models of their manufacturing facilities and processes could be stolen.

Ethical considerations

As pharmaceutical manufacturers harness the power of advanced technologies, they must also address ethical considerations surrounding data privacy, security, and algorithmic bias.

Robust data governance frameworks and ethical guidelines ensure responsible data and AI use, safeguarding patient

privacy and upholding ethical principles.

Regulatory frameworks such as the EU's General Data Protection Regulation and the US Health Insurance Portability and Accountability Act mandate strict guidelines for the collection, storage, and use of patient data. Organizations such as the Partnership on AI and the IEEE Global Initiative on Ethics of Autonomous and Intelligent Systems are developing ethical guidelines for AI development and deployment.

The new skills needed

The journey to intelligent manufacturing is well under way, marked by both incremental advances and transformative initiatives across the pharmaceutical landscape. However, this potential will be realized only if workers with the relevant skills are readily available.

As manufacturing becomes more digital, companies need workers with new skills beyond traditional production. Intelligent factories need employees who understand pattern recognition, algorithms, and statistics so they can assess, analyze, and manage data that must be shared and used. Manufacturing faces a massive skills shortfall for the rest of this decade, as a projected 2.1 million of 4 million manufacturing jobs could go unfilled. Many of these shortages relate to wider labor trends, such as a lack of data scientists and analytical competencies. While remote working increases the potential talent pool, it also increases demand for those collaboration skills as they work at a distance

from physical plants and from each other.

The industry is experimenting with creative new ways to address its skills shortage. In the UK, the University of Birmingham is leading a training initiative that is virtual reality-enabled, giving students a realistic experience of manufacturing work. It also includes training in data and analytics, AI, and other digital skills.

As new technologies have become established, manufacturing has evolved beyond human-to-machine collaboration to machine-to-machine collaboration. However, machines should augment, not replace human involvement, and they can increase worker effectiveness. David De Cremer of Northeastern University and chess legend Garry Kasparov make the case that AI and authentic intelligence are complementary, rather than opposites. They argue that the intuitive, emotional, and culturally sensitive abilities of humans are needed, as is AI speed, accuracy, and rationality. "The question of whether AI will replace human workers assumes that AI and humans have the same qualities and abilities — but, in reality, they don't," they wrote in Harvard Business Review.

A vision for intelligent manufacturing offers leaders a way to navigate a complex and demanding operational landscape. Pharmaceutical manufacturing technology may provide the tools, but humans and their continuously evolving skills will be needed to achieve the industry's full potential and shape a brighter future for patients and society.



Trend 6: The new pharma supply chain: Collaboration and data

- Pharma companies strengthened supply chain resilience during the Covid-19 pandemic, but new technologies and threats demand continuing development to minimize vulnerabilities.
- Pharma and healthcare firms are using digital tools such as AI, machine learning, and networked devices to gather data and generate insights from that data to build more responsive supply chains.
- We expect the supply chains of the future will be capable of real-time, highly accurate demand sensing, process control, and risk mitigation finally approaching the 30-year vision of carbon-free, lights-out supply chains.

Advances in new therapies, such as chimeric antigen receptor T-cell (CAR-T) therapy, which uses genetically altered immune cells to fight cancer, and gene therapy, have created new business models for drug development, production, and delivery. These innovations promise to save more than a million lives in the coming decades. However, desired health

outcomes will occur only if supply chains that support these increasingly sophisticated healthcare solutions function optimally.

The Covid-19 pandemic, global conflict, and climate change effects have sharply demonstrated how vulnerable supply chains are to disruption. Technology to solve these

problems offers both potential promise as well as peril. AI, machine learning (ML), and internet of things (IoT) provide life sciences companies with greater visibility into supply chain activity and performance. At the same time, these technologies introduce additional points of vulnerability, from cybersecurity risks to technical failures.

Supply chain innovation and resilience require a data-centric approach and understanding of shortcomings to affordably and reliably facilitate the complex production of new drug therapies.

Solutions include made-to-order supply chains that meet pharma's needs across scheduling, logistics, patient care, and resource management. Additionally, supply chain operations require more visibility to avoid and mitigate shortages that rapidly become critical in a health crisis.

Supply chains must continuously evolve to deliver these therapies, while at the same time making their supply chains more resilient. In the longer term, we expect that through investments in technology, partnerships, and new technologies, a new era of supply chains is just at the horizon. These supply chains will not only deliver new therapies at scale; they will also be greener, with more visibility and transparency.

Public-private partnerships

The modern global supply chain model developed over decades with a simple goal: make products — from mobile phones to medications — cheap, plentiful, and fast. The

just-in-time system was a spectacular success, until the Covid-19 pandemic and wars in Europe and the Middle East demonstrated the fragility of these intricate and often opaque networks.

Shortages of common goods frustrated consumers worldwide in 2020 at the start of the pandemic. In the life sciences and healthcare industries, inconveniences turned into tragedies. Shortages of N95 masks, surgical gloves, and ventilators threatened healthcare workers and forced many to consider supply chain implications for the first time. The surge in demand for some medications created breakdowns in supply networks due to shortages and inefficient allocation — compounded by staffing shortages of frontline workers.

Supply chain disruptions in life sciences continued well past the worst of Covid-19. As of spring 2024, US drug shortages reached an all-time high, with more than 320 drug shortages, including life-saving drugs and those critical for daily functioning such as ADHD medications. Some first-line chemotherapy drugs were among those in short supply and ultimately were rationed.

Industry decision-makers must act decisively to overhaul this system to minimize future vulnerabilities. At the same time, they must balance cost pressures from persistent inflation and meet dozens of regulatory requirements from multiple international agreements and organizations.

Public-private partnerships will also be important to create more resilient supply

chains. Srinivas Chilukuri of Infosys Consulting explains the importance of partnerships to ensure that products are available to patients wherever they are, whenever they need them, in case of emergencies.


Companies need to establish these partnerships across their entire value chain — not just in transportation, manufacturing, or contract domains (Figure 1). For example, a company managing cold chain logistics will need to have such partnerships in place

closer to their markets. A company might need to ship a product, by-product, or even semi-finished product from one country to another. Existing partnerships will be essential to ensure successful shipment, especially in emergencies.

How data boosts efficiency

The stakes could not be higher in the global life sciences supply chain to achieve its fundamental purpose: evolve quickly to

Figure 1. Partnerships at each point in the clinical supply chain build resilience



Source: Infosys Knowledge Institute

grow and serve the market, while mitigating vulnerability and risk. Fortunately, technology tools to reinvent supply chains already exist, such as AI, ML, and IoT.

“New technologies enable supply chain executives to create differentiated and meaningful business capabilities while still achieving high levels of platform simplification and standardization,” says Edward Francis, partner, health and life sciences, Infosys Consulting.

AI is already helping businesses lower operating costs, improve route calculations, and reduce risks. Gartner’s Supply Chain Executive report found high-performing companies were two to three times more likely to use AI and ML in supply planning, logistics, and distribution.

Similarly, IoT’s ability to communicate between devices and locations makes it an effective tool for life sciences supply chains. An exhaustive literature review of IoT’s impact on supply chains — published in the journal Internet of Things — found that IoT improved process performance and transparency, both critical supply chain issues.


Indeed, life sciences companies plan to prioritize investments in flexible supply chain modeling, planning and transparency solutions, and digitalization in the next five years (see Figure 2). However, smaller companies (those with revenues between \$1 billion and \$3 billion) indicate they will prioritize investments in planning and transparency more than larger companies (those with revenues greater than \$3 billion).

Regardless of size, companies plan to invest in these areas more than in flexible supply chain models.

Healthcare providers and life sciences companies are integrating these technologies into supply chains and delivering benefits such as improved analytics and accurate disruption forecasting. This is particularly valuable in drug development, from sourcing materials to effectively transporting goods between locations and cleanrooms.

Drug delivery supply chains enabled by AI, ML, or IoT technology could increase effectiveness exponentially, as each transaction allows the technology to learn, compound its understanding, and further improve the process. For example, AI evaluates inventory variations and supply interruptions more thoroughly, finding

Figure 2. Smaller life sciences firms will prioritize supply chain transparency in the next five years



Source: Infosys Knowledge Institute

patterns and causality previously not possible with traditional analysis techniques.

Tech for resilient supply chains

No supply chain will ever be completely disruption-proof, given the inherent unpredictability of global events. However, AI and ML offer potent tools that can develop insights from data, increasing the ability to predict disruptions faster and more accurately, and then recommend effective corrective actions.

Increased use of generative AI will transform several supply chain areas (Figure 3). We asked respondents which supply chain generative AI use cases currently achieve return on investment (ROI) and which ones they expected to achieve ROI in the next three years. Some 10% of respondent companies already see positive ROI from flexible supply chain modeling and supply chain resilience use cases. Over 90% of


respondents expect that generative AI use cases will show ROI, as well as in visibility and sustainability use cases, in the next three years.

New therapies, new methods

Groundbreaking work in cell and gene therapy has led to a rapid evolution of the traditional supply chain model. These new therapies are tailored to each patient and require a different approach that will be distribute to patients faster and more reliably. Chain of custody and chain of identity are important supply chain metrics for cell and gene therapy, providing visibility to ownership along the supply chain. It also aligns partners to corporate quality standards as the product moves through the supply chain.

Local partnerships, such as apheresis centers (blood banks) and contract manufacturing organizations (CMOs), are important for cell

Figure 3. Generative AI has already begun to prove ROI in supply chain, and expectations are high



Note. Percentages do not total to 100 due to rounding.

Source: Infosys Knowledge Institute

and gene therapy production and delivery. Supply chain visibility is especially critical to this new generation of treatments. Cell and gene therapies need to be stored and transported at cryogenic temperatures (minus 150 degrees Celsius) and must be monitored closely throughout their life cycle.

Since these personalized cell therapies are developed from the patient's cells, the chain of custody is essential. (See also Trend 7, this volume, for more on partnerships and ecosystems in life sciences.)

While all drug development requires effective supply chains, novel cell and gene therapies present, well, novel challenges. They require major changes to supply chain infrastructure, such as how material is handled, routes are mapped, and timelines are planned.

A prime example is CAR-T therapy, which engineers more effective versions of naturally occurring immune cells to target cancer cells. This system attacks solid tumors and fights cancers with high mortality rates. However,

CAR-T therapies are relatively new modalities, and their effectiveness is constrained by aging supply chain infrastructure. Engineered CAR-T cells typically must be delivered to the patient within 48 hours.

While CAR-T is one of the better-known breakthroughs, it is only the start of this therapeutic revolution. Seven gene therapies were approved by the US Food and Drug Administration in 2023, with more than 500 therapies in the pipeline. Immunotherapies offer great hope for those with serious diseases, but these treatments are also more vulnerable to disruption than most medications.

Life sciences firms have invested into their supply and distribution networks over many years. The significant physical and digital supply chain infrastructure in place is a mixed blessing.

While these assets provide an existing foundation, their legacy nature also suggests modernization will be required to take

“

New technologies are enabling supply chain executives to create differentiated and meaningful business capabilities while still achieving high levels of platform simplification and standardization.

Edward Francis

Partner, health and life sciences, Infosys Consulting

”

advantage of the new tech. Our survey found lower priority for investment in supply chains in other areas. Leaders must integrate the power of AI, ML, and IoT technologies to generate the improvements needed while operating within budget constraints.

New tech creates new risks

Although modern supply chains solve many problems, they will also likely create new ones. Life sciences companies must contend with — or even better, anticipate — new vulnerabilities that emerge.

An Organization for Economic Co-operation and Development report found that the life sciences industry is particularly vulnerable to counterfeiting. These vulnerabilities highlight the need for data-driven solutions that increase visibility, yet even the solutions create further risks. As supply chain managers rely on technologies like AI, ML, and IoT, cybersecurity inevitably becomes a major consideration.

Cybercriminals frequently target life sciences companies by seeking sensitive —and commercially valuable — information from their suppliers, distributors, and customers, from intellectual property to patient data.

In the US, cybercrime across industries costs \$320 billion in 2023 and is projected to increase to \$452 billion in 2024. Medical records are significant commodities targeted by cybercriminals. A single data breach for a life sciences company costs \$7.1 million on average.

Adoption priorities

Supply chain development and operation is not static: for life sciences, it should be viewed as an organic entity with flows across its network nodes. Routes, plans, and relationships must be nurtured, developed, and even completely reimagined as needed.

The book *The Live Enterprise* (McGraw-Hill, 2021) explores this concept, comparing supply chains to living organisms that continually evolve and adapt to their shifting environment. This is possible only when architecture is designed to evolve, and life sciences leaders must incorporate this capability into their operating models to increase supply chain resilience. Three fundamental requirements are needed to optimize supply chain management in life sciences.

First, adopt effective technology. While no technology guarantees a perfect supply chain for all life sciences and drug development needs, ML techniques and AI tools have already demonstrated measurable impact on this industry, even as they continue to evolve and mature. Supply chain asset and technology investment should be a priority. While supply chain investment doubled in the last two years, leaders now say that other areas such as generative AI will be a higher priority over the next five years. Supply chain use cases must articulate their value to benefit from continued investments.

Second, prioritize resilience and visibility. Supply chain resilience and visibility are traditional fault lines in product fulfillment,

and a lack of resilience can cause very disruptive fissures. Building a resilient supply chain involves diversifying suppliers, developing contingency plans, and implementing risk management strategies. This ensures that companies can quickly respond to disruptions and maintain continuity of supply.

Finally, aggressively collaborate with external partners, including technology providers, logistics companies, and regulatory bodies, to boost supply chain efficiency and innovation. Strategic partnerships also help companies navigate complex regulatory environments and access new markets.

The pharma industry supply chain faces many challenges, from regulatory complexities and disruptions to cost pressures and the need for technological integration.

However, by embracing advanced digital technologies, sustainable practices, and a patient-centric approach, the industry can build more resilient and efficient supply chains that are responsive to future demands.

The pharmaceutical supply chain is on a journey to optimization and resiliency — ensuring that transformative new life-saving medicines can reach patients promptly and safely.



Trend 7: Knowledge sharing and data integration build stronger healthcare ecosystems

- Companies are shifting their perspective from treating data and clinical evidence as proprietary and private to joining more open and collaborative ecosystems, sharing to convert data into insights and evidence.
- Researchers can use artificial intelligence (AI) and other technologies to more effectively discover, access, and navigate data in the healthcare ecosystem.
- We expect that data and evidence integration across the healthcare ecosystem will lead to transformative new products, drugs, and treatments, and will bring commercial success for more participants.

Data is vital to pharmaceutical companies across discovery, patient enrollment, clinical trials, and commercially, to prove and improve the real-world impact of medicines.

Complex and increasingly diverse data sources are accessed across the value chain for data science and research and commercial

practitioners to convert into actionable insights and clinical evidence. Increasingly, a significant amount of previously proprietary data is now shared in an open, collaborative, and federated healthcare ecosystem, as discussed in a recent Financial Times panel with Subhro Mallik, executive vice president and head of life sciences, Infosys.

Companies need the capability to link internal insights and evidence across firms. This is essential for greater drug discovery, commercial success, improved drug development, and efficacy across the ecosystem. However, inter-enterprise flows increase complexity, as parties collaborate and compete at the same time, sometimes in the same space. Life sciences firms need strong governance and data-sharing policies to negotiate permissions for introducing and accessing external data sources.

R&D and commercial data integration extend beyond individual enterprises. AI and other tools will be useful in this open environment to rapidly normalize and join up data as it enters from disparate sources before it is used in data models and analyses.

Open and federated healthcare

Competition traditionally drives company innovation and operations excellence. As a logical result, businesses keep private plans, proprietary knowledge, and intellectual property as competitive differentiation against their rivals. While seeming locally optimal, this approach fails in the aggregate because life sciences innovation and healthcare improvements require data from multiple sources across the healthcare industry.

The development of an early Covid-19 vaccine — in months, not years — was the result of the collaboration between Pfizer and BioNTech and multiple healthcare and population health ecosystems. More recently, public-private partnership between the

Pharma Proteomics Project, a pharmaceutical consortium, and UK Biobank, a large-scale biomedical database of genetic, lifestyle, and health information, worked together to share results of a large study of genetic variation in proteins that will accelerate the development of biomarkers, predictive models, and therapeutics.

The need for competitor collaboration and coordination is driven by three factors happening in parallel. First, available data in the sector is surging. Second, there is a strong demand for real-world evidence (RWE) of product safety and efficacy, backed up by real-world data (RWD). The RWE solutions market is expected to more than double in the next five years, from \$2 billion in 2024 to \$4.5 billion in 2029. And third, the need for diversity and inclusion in trials is increasing.

Healthcare stakeholders, from physicians to pharmaceutical companies to regulators, increasingly recognize the importance of RWE and RWD. The US Food and Drug Administration created a regulatory framework using RWE to “support new indications for already approved drugs or biologics and post-approval studies.” Similar efforts are happening in Europe, seeking to use RWE to improve regulatory decision-making. This momentum has spurred corporate partnerships, increased private-public partnerships, and created the need for new guidelines for using RWE and RWD.

Even so, RWD is only a fraction of the data that the healthcare industry generates and consumes. The World Economic Forum estimates that in the next seven years,


30% of the world's data will be generated by the healthcare sector, especially with the rise of wearables (see also Trend 2 in this journal). The sources of data the healthcare and life sciences consumes is also increasing. They include, for instance, social determinants of health, more diverse and inclusive clinical trials, personal datasets, and behavioral science.

Behind all of this is the recognition of the ways that a wide array of data will make treatments more personalized, more precise, and ultimately more effective. This enormous amount of data will remain underutilized without a strong sharing ecosystem among R&D organizations, patient service settings, and commercial companies — and the potential for greater drug discovery and development, commercial success, and transformative healthcare outcomes.

Pfizer executive John Pastor describes companies as “going through a big mind shift” and realizing that they need to be able to analyze data where it resides. To do that, companies can leverage their partners.

Indeed, life sciences executives say they will increase spending on data integration. Data integration has long been important to global enterprises, as for decades they have slowly linked internal data repositories and applications to gain a comprehensive view of their enterprise. Now they realize the importance of doing the same across companies. The Infosys Knowledge Institute survey of life sciences executives found that 61% intend to significantly increase spending on data integration in the next five

Figure 1. Nearly all executives plan to increase spending on data integration in the next five years



Source: Infosys Knowledge Institute


years (Figure 1). Most others anticipate some increase in data integration over that time.

Sharing goes beyond data

Beyond data, other pre-competitive information should also be shared, according to panelists at a recent forum organized by the Financial Times. Data assets, products, models, evidence, and many other evidence-generating assets must be integrated and shared across the ecosystem.

Executives from Infosys, MSD, and Novo Nordisk discussed the need for stakeholders to share general lessons with peers and among biotech, tech giants, and startups; knowledge of technology with regulators; and taxonomies, ontologies, and models across the healthcare ecosystem (Figure 2). Subhro Mallik of Infosys said this is changing so fast that firms will be left behind if they don't leverage their entire ecosystem.

Figure 2. Ecosystems close the data–evidence loop to link the commercial and R&D domains



Source: Infosys Knowledge Institute

Although companies have collaborated on R&D since the 1990s, the scale has taken off in recent years. This is driven by incremental value from the massive quantities of data that are produced, and tech advancements that enable sharing that is safe, protects privacy, and complies with regulations.

Sometimes the goal of collaborating is to create frameworks for future collaborations. For example, the Pistoia Alliance created an ontology for interoperability and collaboration among international companies. This aids compliance with the International Organization for Standardization (ISO) standards for the Identification of Medicinal Products (IDMP), mandated by the European Medicines Agency.

By solving ambiguities in this ISO standard, it also avoids future interoperability risks when ecosystem partners work together on, for example, R&D. Eleven pharmaceutical

companies, regulatory bodies, standards organizations, and nonprofits worked together to create this ontology.

AI concierge for ecosystems


David Champeaux, lead partner, health and life sciences, EMEA, Infosys Consulting, describes how this ecosystem integration introduces an order of magnitude of complexity over integrating data within an organization. Part of this integration, he says, is navigating the systems and permissions to find the data, models, and evidence needed, like a pharmaceutical company conducting research. The researcher needs to first discover the existence of relevant datasets.

Then, they request permission to access these datasets to run algorithms on them, or even identify relevant evidence-generating methods and models to run on them.

Beyond finding and accessing data, the researchers need governance to ensure they're using the data ethically and respecting the constraints of the terms of access they've been given. Technology can enable data discovery and then navigate the permission. For example, AI tools could help a researcher quickly navigate to a network of datasets and request access. The AI in effect becomes a navigation agent, a concierge.

Our survey found that life sciences executives intend to invest in AI to enhance data navigation and interoperability, and that AI tools for data navigation and linkage are the top area of investment in data integration (Figure 3).

Figure 3. Life sciences companies prioritize data-related AI investments



Note. Percentages do not total to 100 due to rounding.

Source: Infosys Knowledge Institute

Other technology and tools

In addition to AI, other ecosystem integration tech and tools include cloud, microservices, and interoperability standards. For example, Champeaux describes a decentralized research scenario of a pharma researcher seeking insights on population health. To develop the insight, they require access to data owned by multiple hospital groups and application of a model developed by an AI startup.

The researcher could leverage a contract to give permission to an algorithm to process that data, output the insight, pay the data and algorithm owners and enforce governance via AI-enabled permissions. This would be orchestrated under a blockchain paradigm that enables complete process traceability.

Life sciences companies need to continue their evolution toward ecosystem-wide collaboration and find the tools and tech

to achieve it, even though they might find it difficult to shift their mindsets in order to pursue open collaboration, simultaneously navigate collaboration and competition, and intentionally share knowledge with rivals.

However, there are downsides to not sharing. Without collaboration and ecosystem success, non-collaborative parties will be left behind, potentially at patients' expense.

In 2020, Stephanie Reel, chief information officer of the Johns Hopkins Health System, expressed the need to protect intellectual property while also worrying about a lack of data sharing. "I don't want us to [be] too careful and too controlling because I think there is some risk that we will not make that next big discovery or cure that dreadful form of cancer," she told Becker's Health IT.

Cybersecurity presents an additional strategic concern, as companies face two conflicting interests: openness to share data while

recognizing that open AI frameworks are more attractive to cybercriminals than closely held, secure information.

The regulation landscape will play a critical role in how collaborations happen. In the US, sharing will likely be left to individual entities at large. However, the highest amount of healthcare data will be generated by India and China – two of the world's most populous countries. These countries may take a different approach, one more driven by governmental oversight and management.

At the technical level, integrating data across organizations requires normalization of datasets to a common standard so researchers can use them. For instance, electronic medical records from 10 hospitals may be structured in 10 different ways. The data might not even be structured.

Even after data normalization, data from many different sources must be linked, which represents another significant challenge. A researcher may need to link datasets containing demographic information (like

social determinants of health) with patient data that is based on physical health. This is a hugely complex challenge – the linkage must preserve patient privacy while still capturing the information in the dataset. Resolving identities across datasets, first to de-identify data and then to create the linkages, is an ideal use for deep learning.

Data in an ecosystem

AI-enabled knowledge graphs, when combined with robust metadata management, create powerful linkages, and provide deeper insights. Knowledge graphs integrate data points from various sources and reveal relationships between them.

Adding metadata enhances the data's context, consistency, and interoperability. In RWE, enriched knowledge graphs link clinical trial data, electronic health records, patient-reported outcomes, and social determinants of health, uncovering complex patterns and relationships. This combination facilitates actionable insights, improves decision-making, and leads to better patient outcomes

“

Healthcare is pivoting from one-size-fits-all, bulk-manufactured drugs to more individualized medication and treatments. Integration of data and sharing of knowledge are foundational to advancing healthcare quality, and innovation.

Vivek Ruikar

Vice president, Infosys Life Sciences

”

and more effective treatments.

A company's enterprise architecture can support data integration across the ecosystem, as well as guide AI-first transformation by organizing technology to support business strategy.

Marcello Di Maulo of Infosys Consulting explains that by integrating AI, machine learning (ML), and MLOps frameworks in a comprehensive RWE data management system, a company can connect the dots between people, business, and technology at an enterprise ecosystem level. This enhances collaboration and drives transformative outcomes across the healthcare ecosystem.

While data integration is a catalyst for ecosystem value creation, success requires more than tech. Human collaboration will remain important for learning, governance, exception management, and ensuring that all parties benefit from the arrangement.

As a recent article on pre-competitive collaborations describes, pharmaceutical companies need to decide which collaboration domains they will pursue. Examples include basic biology; biomarkers of prognosis, diagnosis, and treatment; drug discovery, development, and response; and knowledge and research design like hypothesis development.

They also need to define their collaboration goals, and the right forum, governance, and business models required to achieve those goals (open vs. restricted, consortium, public-private partnership, innovation center). They should also define metrics for successful collaboration and chart a path to achieve them, including understanding barriers.

Effective collaboration in the healthcare ecosystem will require organizational change, as it is a mindset shift from competitive protection to enlightened self-interest. Companies need to evaluate their skills, talent, technology, and other resources to collaborate effectively. This includes reviewing policies on data sharing, ethical use of data, compliance, and governance.

Data and evidence are the lifeblood that sustains the healthcare ecosystem, and integration is its force multiplier in the AI era. This capability will aid discovery, increase drug efficacy, and improve patient outcomes — while driving operational excellence.

In the last decade, digital transformation in life sciences provided a technological foundation. In the next decade, data and evidence integration will enable companies to thrive individually and as a cohesive industry with common interests, so the healthcare ecosystem can deliver on its promise.

Selected references*

Trend 1

1. For pharmaceutical companies, three steps to value with generative AI, Bernd Ziegler et al., January 24, 2024, BCG.
2. Generative AI brings great potential – and risks – to payer space, Noah Tong, August 8, 2023, Fierce Healthcare
3. Generative AI radar, Samad Masood, Kate Bevan, Harry Keir Hughes, and Jeff Mosier, 2024, Infosys Knowledge Institute.
4. NHS AI test spots tiny cancers missed by doctors, Zoe Kleinman, March 21, 2024, BBC.
5. Cancer overdiagnosis, Cancer Research UK, n.d.
6. AI in drug discovery and its clinical relevance, Rizwan Qureshi et al., July 2023, Heliyon, Vol. 9.
7. Generative AI develops potential new drugs for antibiotic-resistant bacteria, Rachel Tompa, March 28, 2024, Stanford News.
8. Artificial intelligence in pharmaceutical technology and drug delivery design, Lalitkumar K. Vora et al., July 2023, Pharmaceutics.
9. How AI is being used to accelerate clinical trials, Matthew Hutson, March 2024, Nature.
10. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence, Jan-Niklas Eckardt et al., March 2024, Nature.
11. Harnessing synthetic data for human-centric AI, Karthik Nagarajan, December 2023, Infosys.
12. Impact of a deep learning sepsis prediction model on quality of care and survival, Aaron Boussina et al., January 2024, Nature.
13. Generative AI will transform health care sooner than you think, Matthew Huddle, Josh Kellar, Krishna Srikumar, Krishna Deepak, and Daniel Martinez, June 2023, BCG.
14. Solving the AI black box problem through transparency, Cassidy Kelley and Benjamin St. George, August 2021, TechTarget.

Trend 2

1. Meta-analysis of studies on the effects of digital therapeutics, Young-Chul Seo, Sang Yeol Yong, Won Woo Choi, Sung Hoon Kim, and Enrico Capobianco, February 2024, Journal of Personalized Medicine.
2. Leveraging machine learning to examine engagement with a digital therapeutic, Andrew C. Heusser, Denton J. DeLoss, Elena Cañadas, and Titiimaea Alailima, June 2023, Frontiers in Digital Health.

3. 3 ways generative AI is reshaping the patient experience, Pratap Khedkar and Shyam Bishen, January 2024, World Economic Forum.
4. Digital therapeutics can improve medication adherence in diabetes, Tejas Kamat, November 2020, Journal of Family Medicine and Primary Care.
5. Bloomer Tech receives \$1.9M from the NIH for a clinical study in women's heart health, November 2023, FemTech Insider.
6. Neurological wearables for clinical diagnostics and therapeutic interventions, Dr. Ryan Peters, MDPI.
7. Digital therapeutics, Dina Kampouraki, EDPS.
8. Open challenges in developing digital therapeutics in the United States, Brenda Y. Miao, Douglas Arneson, Michelle Wang, and Atul J. Butte, January 2022, PLOS Digital Health.
9. Role of digital therapeutics and the changing future of healthcare, Amit Dang, Dimple Arora, and Pawan Rane, May 2020, Journal of Family Medicine and Primary Care.
10. The digital therapeutics real-world evidence framework: An approach for guiding evidence-based digital therapeutics design, development, testing, and monitoring, Meelim Kim et al., March 2024, Journal of Medical Internet Research.
11. Assessing the Longitudinal Impact of Physician-Patient Relationship on Functional Health, R. Henry Olaisen et al., September 2020, Annals of Family Medicine.
12. Ensuring public trust in digital therapeutics: a pharmacopeial perspective, Michael Ambrose, April 2021, Journal of Managed Care + Specialty Pharmacy.
13. Digital therapeutics from bench to bedside, Changwon Wang, Chungkeun Lee, and Hangsik Shin, March 2023, Nature.

Trend 3

1. How AI relationship intelligence boosts medical sales, Kevin Chien, December 2021, Salesforce.
2. Flexible and fit for purpose: Hybrid sales in Medtech, Mayuri Shah, Lori Sherer, and Andrey Voytenko, May 2023, Bain & Company.
3. New trends in sales force organization, Nicholas Basta, June 2023, Pharmaceutical Commerce.
4. Why health care workers are burning out, Noah Weiland, October 2023, The New York Times.
5. 3 insights on HCP access to help improve field activities, Dan Rizzo, December 2022, Veeva.
6. Big majority of doctors see upsides to using health care AI, Andis Robeznieks, January 2024, AMA.

Trend 4

1. Decentralized clinical trials for drugs, biological products, and devices, May 2023, US FDA.
2. Early termination of oncology clinical trials in the United States, Ellen Zhang, Steven G. DuBois, October 2022, Wiley.
3. Comparison of study samples recruited with virtual versus traditional recruitment methods, Heidi Moseson, Shefali Kumar, Jessie L. Juusola, September 2020, ScienceDirect.
4. Force for good, Annual Report 2022-23, Cipla.
5. Inclusion and diversity in clinical trials: Actionable steps to drive lasting change, Michelle D. Kelsey et al., May 2022, ScienceDirect.
6. Diversity and inclusion in clinical trials, January 2024, NIMHD.
7. Big Pharma bets on AI to speed up clinical trials, Natalie Grover and Martin Coulter, September 2023, Reuters.
8. Data integrity and governance: building trust and transparency in clinical trials, March 2023, Alba Rosa and Danial Khan, ResearchGate.

Trend 5

1. How Gene Therapy Can Cure or Treat Diseases, July 2022, US FDA.
2. An audit of pharmaceutical continuous manufacturing regulatory submissions and outcomes in the US, Adam C. Fisher et al., June 2022, ScienceDirect.
3. Big data collection in pharmaceutical manufacturing and its use for product quality predictions, Janja Žagar and Jurij Mihelič, March 2022, Nature.
4. Modernizing FDA's new drugs regulatory program, December 2023, US FDA.
5. How is the EU boosting support for innovation in the health sector? October 2023, Euronews.
6. Quality metrics for drug manufacturing, April 2024, US FDA.
7. Digital health Software Precertification (Pre-Cert) Pilot Program, September 2022, US FDA.
8. Digital collaboration aims to bring new medicines and treatments to patients up to 1 year faster, April 2024, CPI.
9. Industrializing AI/ML during the end-to-end drug discovery process, Jiho Yoo, Tae Yong Kim, InSuk Joung, and Sang Ok Song, April 2023, ScienceDirect.
10. Integrating Artificial Intelligence for Drug Discovery in the Context of Revolutionizing Drug Delivery, Anita Ioana Visan and Irina Negut, February 2024, Life (Basel).

12. Creating pathways for tomorrow's workforce today: Beyond reskilling in manufacturing,
13. Future vaccine makers to get VR-assisted training centre of excellence, March 2024, University of Birmingham.
14. Is industrial automation headed for a tipping point? Harald Bauer, David Ebenstein, Giuletta Poltronieri, and Jan Paul Stein, June 2023, McKinsey & Company.

Trend 6

1. US drug shortages reach record high with 323 meds now in short supply, Beth Mole, April 2024, Ars Technica.
2. Artificial intelligence in pharmaceutical technology and drug delivery design, Lalitkumar K. Vora et al., July 2023, Pharmaceutics, Pharmaceutics.
3. Distribution and supply chain models in the cell and gene therapy landscape, June 2021, Deloitte.
4. CAR T Cells: Engineering patients' immune cells to treat their cancers, March 2022, National Cancer Institute.
5. Spotlight on gene therapies in Q2 2024 trends, April 2024, Segal.
6. Trade in counterfeit pharmaceutical products, March 2020, OECD.
7. Innovation ramps up as firms invest in supply chain, Brian Straight, November 2023, SCMR.

Trend 7

1. The next stage of pharma's big evolution, Bijoy Sagar, Chair, with Catherine Abi-Habib, Subhro Mallik, Shobie Ramakrishnan, Diane Wuest, and Hannah Kuchler, July 2022, Financial Times webinar.
2. Plasma proteomic associations with genetics and health in the UK Biobank, Benjamin B. Sun, October 2023, Nature.
3. The new FDA real-world evidence program to support development of drugs and biologics, David C. Klonoff, March 2020, Journal of Diabetes Science and Technology.
4. Real-world evidence framework to support EU regulatory decision-making, September 2021-February 2023, EMA.
5. Real-world evidence: A primer, Amit Dang, January 2023, Springer Nature.
6. The precompetitive space for drug or vaccine development: what does it look like now and what could it look like in the future? Jeffrey S. Barrett, October 2023, The Journal of Pediatric Pharmacology and Therapeutics.
7. *For the full list of references, please see the online version of this publication at infosys.com

Lead author

Jeff Kavanaugh | Global head, Infosys Knowledge Institute

Contributors

Phil Benton | Partner, AI experience transformation, Infosys Consulting

Anne Bichteler | Senior principal, health and life sciences, Infosys Consulting

David Champeaux | Lead partner, health and life sciences, EMEA, Infosys Consulting

Srinivas Chilukuri | Associate partner, Infosys Consulting

Marcello Di Maulo | Senior principal data analytics, health and life sciences, Infosys Consulting

Surya Duvvuri | Vice president, Infosys Life Sciences

Edward Francis | Partner, health and life sciences, Infosys Consulting

Marta Hernandez | Business development executive, health and life sciences, Infosys Consulting

Sudip Hui | Senior director, life sciences and healthcare, Infosys Engineering

George Hunnewell | Senior vice president and general manager, US, BASE life science

Prabhat Kaul | Vice president, Infosys Life Sciences

Ashish Mishra | Associate vice president
Infosys Life Sciences

Luca Morreale | Chief commercial officer, BASE life science

Suresh Ramasubbu | Vice president, Infosys Life Sciences

Ashutosh Raut | Client solution head, Infosys Life Sciences

Thomas Røhme | Vice president, data and analytics, BASE life science

Gurdeep S. Rooprai | Associate vice president, Infosys Life Sciences

Vivek Ruikar | Vice president, Infosys Life Sciences

Ian Storr | Associate partner, health and life sciences R&D lead, EMEA, Infosys Consulting

Martin Woergaard | Chief executive officer, BASE life science

Editor

Nikki Seifert, PhD | Infosys Knowledge Institute

Editorial and production, Infosys Knowledge Institute

Kate Bevan, Jeff Mosier, Chad Watt, Pragya Rai,
Snehal Bhosale, Isaac LaBauve, Pramath Kant,
Dylan Cosper, Nithin T P

About Infosys Knowledge Institute

The Infosys Knowledge Institute helps industry leaders develop a deeper understanding of business and technology trends through compelling thought leadership. Our researchers and subject matter experts provide a fact base that aids decision making on critical business and technology issues.

To view our research, visit Infosys Knowledge Institute at infosys.com/IKI or email us at iki@infosys.com.



For more information, contact askus@infosys.com



© 2024 Infosys Limited, Bengaluru, India. All Rights Reserved. Infosys believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Infosys acknowledges the proprietary rights of other companies to the trademarks, product names and such other intellectual property rights mentioned in this document. Except as expressly permitted, neither this documentation nor any part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, printing, photocopying, recording or otherwise, without the prior permission of Infosys Limited and/ or any named intellectual property rights holders under this document.